

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number
WO 02/064590 A2(51) International Patent Classification⁷: C07D 471/04, 519/00, A61K 31/437, A61P 9/00, 15/10 // (C07D 471/04, 221:00, 209:00) (C07D 519/00, 471:00, 471:00)

(21) International Application Number: PCT/US01/49393

(22) International Filing Date:
18 December 2001 (18.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/268,158 12 February 2001 (12.02.2001) US

(71) Applicant (for all designated States except US): LILLY ICOS LLC [US/US]; 1209 Orange Street, Wilmington, DE 19801 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SAWYER, Jason, Scott [US/US]; 5718 North Winthrop Avenue, Indianapolis, IN 46220 (US). ORME, Mark, W. [US/US]; 4235 Francis Avenue #203, Seattle, WA 98103 (US). BOM-BRUN, Agnes [FR/FR]; Maison Cloni, 1153 Route de Saleve, F-74560 Monnetier Mornex (FR). BOUILLOT, Anne [FR/FR]; Centre de Recherche Glaxo Smith Kline Courtaboeuf, ZA de Courtaboeuf, 25, avenue de Quebec, F-91940 Les Ulis (FR). DODIC, Nerina [FR/FR]; Centre de Recherche Glaxo Smith Kline Courtaboeuf, ZA de Courtaboeuf, 25, avenue de Quebec, F-91940 Les Ulis (FR). SIERRA, Michael [FR/FR]; Centre de Recherche

Glaxo Smith Kline Courtaboeuf, ZA de Courtaboeuf, 25, avenue de Quebec, F-91940 Les Ulis (FR). GOSMINI, Roamin, Luc, Marie [FR/FR]; Centre de Recherche Glaxo Smith Kline Courtaboeuf, ZA de Courtaboeuf, 25, avenue de Quebec, F-91940 Les Ulis (FR).

(74) Agent: NAPOLI, James, J.; Marshall, Gerstein & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL COMPOUNDS



WO 02/064590 A2

(57) Abstract: Compounds of the general structural form- (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.

- 1 -


CHEMICAL COMPOUNDS

FIELD AND BACKGROUND OF THE INVENTION

5 This invention relates to a series of compounds, to methods of preparing the compounds, to pharmaceutical compositions containing the compounds, and to their use as therapeutic agents. In particular, the invention relates to compounds that
10 are potent and selective inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase (cGMP-specific PDE), in particular PDE5, and have utility in a variety of therapeutic areas wherein such inhibition is considered beneficial, including
15 the treatment of cardiovascular disorders and erectile dysfunction.

SUMMARY OF THE INVENTION

20 The present invention provides compounds of formula (I)




- 2 -

wherein R⁰, independently, is selected from the group consisting of halo, C₁₋₆alkyl, aryl, heteroaryl, C₃₋₈cycloalkyl, C₃₋₈heterocycloalkyl, C₃₋₈cycloalkylQ, C(=O)R^a, OC(=O)R^a, C(=O)OR^a, C₁₋₄alkyleneNR^aR^b, 5 C₁₋₄alkyleneHet, C₁₋₄alkyleneC(=O)OR^a, C(=O)NR^aSO₂R^c, C(=O)C₁₋₄alkyleneHet, C(=O)NR^aR^b, C(=O)NR^bR^c, C(=O)-NR^aC₁₋₄alkyleneOR^b, C(=O)NR^aC₁₋₄alkyleneHet, OR^a, OC₁₋₄-alkyleneC(=O)OR^a, OC₁₋₄alkyleneNR^aR^b, OC₁₋₄alkyleneHet, 10 OC₁₋₄alkyleneOR^a, OC₁₋₄alkyleneNR^aC(=O)OR^b, NR^aR^b, NR^bR^c, NR^aC₁₋₄alkyleneNR^aR^b, NR^aC(=O)R^b, NR^aC(=O)NR^aR^b, 15 N(SO₂C₁₋₄alkyl)₂, NR^a(SO₂C₁₋₄alkyl), nitro, trifluoromethyl, trifluoromethoxy, cyano, SO₂NR^aR^b, SO₂R^a, SOR^a, SR^a, and OSO₂CF₃;

R¹ is selected from the group consisting of 15 optionally substituted aryl, optionally substituted heteroaryl, an optionally substituted C₃₋₈cycloalkyl ring, an optionally substituted C₃₋₈heterocycloalkyl ring, an optionally substituted bicyclic ring

20




25

wherein the fused ring B is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one to three heteroatoms selected from oxygen, sulfur, and nitrogen, hydrogen, C₁₋₆alkyl, arylC₁₋₃alkyl, C₁₋₃alkenylene-aryl, haloC₁₋₆alkyl, C₁₋₄alkyleneC(=O)OR^a, C₁₋₄alkylene-C(=O)NR^aR^b, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, C₃₋₈hetero- 30


- 3 -

cycloalkenyl, C₁₋₄alkyleneHet, C₁₋₄alkyleneQR^a, C₂₋₆-alkenyleneQR^a, C₁₋₄alkyleneQC₁₋₄alkyleneQR^a,

5




10



15


20



and a spiro substituent having a structure

25

30



- 4 -

R² is selected from the group consisting of hydrogen, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₃₋₈heterocycloalkyl, C₂₋₆alkenyl, C₁₋₃alkylenearyl, arylC₁₋₃alkyl, aryl, heteroaryl, C(=O)R^a, C(=O)NR^aR^b, C(=O)NR^bR^c, 5 C(=S)NR^aR^b, C(=S)NR^bR^c, OR^a, NR^aR^b, NR^bR^c, SO₂R^a, SO₂NR^aR^b, S(=O)R^a, S(=O)NR^aR^b, C(=O)NR^aC₁₋₄alkyleneOR^a, C(=O)NR^aC₁₋₄alkyleneHet, C(=O)C₁₋₄alkylenearyl, C(=O)-10 C₁₋₄alkyleneheteroaryl, C₁₋₄alkylenearyl, C₁₋₄alkyleneheteroaryl, C₁₋₄alkyleneHet, C₁₋₄alkyleneC(=O)C₁₋₄alkylenearyl, C₁₋₄alkyleneC(=O)C₁₋₄alkyleneheteroaryl, 15 C₁₋₄alkyleneC(=O)Het, C₁₋₄alkyleneC(=O)NR^bR^c, C₁₋₄alkyleneOR^a, C₁₋₄alkyleneNR^aC(=O)R^a, C₁₋₄alkyleneOC₁₋₄alkyleneOR^a, C₁₋₄alkyleneNR^bR^c, C₁₋₄alkyleneC(=O)OR^a, and C₁₋₄alkyleneOC₁₋₄alkyleneC(=O)OR^a;

R³ is selected from the group consisting of hydrogen, C₁₋₆alkyl, haloC₁₋₆alkyl, aryl, heteroaryl, arylC₁₋₃alkyl, heteroarylC₁₋₃alkyl, C₁₋₃alkylenearyl, C₁₋₃alkyleneHet, C₃₋₈cycloalkyl, and C₃₋₈heterocycloalkyl;


20 Y is selected from the group consisting of C(=O), C(=O)Z, SO, SO₂, C(=S), C(R^a)₂, and CR^a=CR^a; Z is (CH₂)_t or C≡C;

A is aryl or heteroaryl and is selected from the group consisting of optionally substituted 5- or 6-membered aromatic rings and optionally substituted fused bicyclic ring systems, either carbocyclic or containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and containing at least one aromatic ring;

30 R⁴ is selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl, heteroaryl, halo, C(=O)OR^b, NHC(=O)C₁₋₃alkyleneN(R^b)₂, NO₂, C(=O)OR^b, OR^b, CF₃, OR^a,

- 5 -

CN, OC(=O)R^b, arylOR^b, Het, NR^aC(=O)C₁₋₃alkyleneC(=O) -
 OR^a, arylOC₁₋₃alkyleneNR^aR^b, arylOC(=O)R^a, C₁₋₄alkylene-
 C(=O)OR^b, OC₁₋₄alkyleneC(=O)OR^b, C₁₋₄alkyleneOC₁₋₄alkyl-
 eneC(=O)OR^b, C(=O)NR^bSO₂R^c, C₁₋₄alkyleneNR^bR^c, C₂₋₆-
 5 alkenyleneNR^bR^c, C(=O)NR^bC₁₋₄alkyleneOR^b, C(=O)NR^bC₁₋₄-
 alkyleneHet, OC₂₋₄alkyleneNR^bR^c, OC₁₋₄alkyleneCH(OR^b) -
 CH₂NR^bR^c, OC₁₋₄alkyleneHet, OC₂₋₄alkyleneOR^b, OC₂₋₄alkyl-
 eneNR^bC(=O)OR^c, NR^bC₁₋₄alkyleneNR^bR^c, NR^bC(=O)R^c,
 10 NR^bC(=O)NR^bR^c, N(SO₂C₁₋₄alkyl)₂, NR^b(SO₂C₁₋₄alkyl),
 SO₂NR^bR^c, OSO₂CF₃, C(=O)R^b, C₁₋₃alkylenearyl, C₁₋₄alkyl-
 eneHet, C₁₋₆alkyleneOR^b, C₁₋₃alkyleneN(R^b)₂, NR^bR^c,
 15 C(=O)NR^bR^c, NHC(=O)C₁₋₃alkylenearyl, NHC(=O)C₁₋₃alkyl-
 eneheteroaryl, C₃₋₈cycloalkyl, C₃₋₈heterocycloalkyl,
 arylOC₁₋₃alkyleneN(R^b)₂, arylOC(=O)R^b, NHC(=O)C₁₋₃-
 alkyleneC₃₋₈heterocycloalkyl, NHC(=O)C₁₋₃alkyleneHet,
 20 NHC(=O)haloC₁₋₆alkyl, and



R⁵, independently, is selected from the
 30 group consisting of halo, NR^aR^b, NO₂, C₁₋₆alkyl, oxo,
 and OR^a;

or R⁴ and R⁵ are taken together to form a
 3- or 4-membered alkylene or alkenylene chain

- 6 -

component of a 5- or 6-membered ring, optionally containing at least one heteroatom;

R^a is selected from the group consisting of hydrogen, C₁₋₆alkyl, cyano, aryl, arylC₁₋₃alkyl, C₁₋₃alkylenearyl, heteroaryl, heteroarylC₁₋₃alkyl, and C₁₋₃alkyleneheteroaryl;

R^b is selected from the group consisting of hydrogen, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₁₋₃alkyleneN(R^a)₂, aryl, arylC₁₋₃alkyl, C₁₋₃alkylenearyl, heteroaryl, heteroarylC₁₋₃alkyl, and C₁₋₃alkyleneheteroaryl;

R^c is selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl, heteroaryl, arylC₁₋₃alkyl, heteroarylC₁₋₃alkyl, C₁₋₃alkyleneN(R^a)₂, C₁₋₆alkylene-aryl, C₁₋₆alkyleneHet, haloC₁₋₆alkyl, C₃₋₈cycloalkyl, C₃₋₈heterocycloalkyl, Het, C₁₋₃alkyleneheteroaryl, C₁₋₆alkyleneC(=O)OR^a, and C₁₋₃alkyleneC₃₋₈heterocycloalkyl;

or R^b and R^c are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;

Q is O, S, or NR^d;

C is O, S, or NR^d;

D is O, S, or NR^a;

E is CR^a or N;

F is CR^a, C(R^a)₂, or NR^d;

R^d is null or is selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl, heteroaryl, arylC₁₋₃alkyl, heteroarylC₁₋₃alkyl, C₁₋₃alkylenearyl, and C₁₋₃alkyleneheteroaryl;

Het is a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the

- 7 -

group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C_{1-4} alkyl or $C(=O)OR^a$;

n is 0 or 1;


p is 0, 1, 2, or 3;

5 q is 0, 1, 2, 3, or 4;

t is 1, 2, 3, or 4;

and pharmaceutically acceptable salts and solvates (e.g., hydrates) thereof.


10 In a preferred embodiment, R^2 and R^3 is hydrogen, q is 0, and the compounds have a structural formula (II):



(II)

20 wherein R^1 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, an optionally substituted bicyclic ring

25



30

wherein the fused ring B is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one to three

- 8 -


heteroatoms selected from oxygen, sulfur, and nitrogen;

Y null or is selected from the group consisting of C(=O), C(=O)C=C, C(=O)(CH₂)_t, SO₂, and 5 C(=S);

A is aryl or heteroaryl and is selected from the group consisting of optionally substituted 5- or 6-membered aromatic rings and optionally substituted fused bicyclic ring systems, either carbocyclic or containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and containing at least one aromatic ring;

R⁴ is selected from the group consisting of 15 hydrogen, C₁₋₆alkyl, aryl, heteroaryl, halo, C(=O)OR^b, NHC(=O)C₁₋₃alkyleneN(R^b)₂, NO₂, C(=O)OR^b, OR^b, CF₃, OR^a, CN, OC(=O)R^b, arylOR^b, Het, NR^aC(=O)C₁₋₃alkylene-C(=O)OR^a, arylOC₁₋₃alkyleneNR^aR^b, arylOC(=O)R^a, C₁₋₄-20 alkyleneC(=O)OR^b, OC₁₋₄alkyleneC(=O)OR^b, C(=O)NR^bSO₂R^c, C₁₋₄alkyleneNR^bR^c, C₂₋₆alkenyleneNR^bR^c, C(=O)NR^bC₁₋₄-alkyleneOR^b, NR^bC₁₋₄alkyleneNR^bR^c, NR^bC(=O)R^c, NR^bC(=O)-NR^bR^c, OSO₂CF₃, C(=O)R^b, C₁₋₃alkylenearyl, C₁₋₄alkylene-Het, C₁₋₆alkyleneOR^b, C₁₋₃alkyleneN(R^b)₂, NR^bR^c, C(=O)-NR^bR^c, NHC(=O)C₁₋₃alkylenearyl, NHC(=O)C₁₋₃alkylene-25 heteroaryl, NHC(=O)C₁₋₃alkyleneC₃₋₈heterocycloalkyl, NHC(=O)C₁₋₃alkyleneHet, NHC(=O)haloC₁₋₆alkyl, and

- 9 -



;

10

R^5 , independently, is selected from the group consisting of halo, NR^aR^b , NO_2 , C_{1-6} alkyl, oxo, and OR^a ;

15 R^a and R^b , independently, are selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, $arylC_{1-3}$ alkyl, C_{1-3} alkylenearyl, heteroaryl, hetero-aryl C_{1-3} alkyl, and C_{1-3} alkyleneheteroaryl;

20 R^c is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, $arylC_{1-3}$ alkyl, heteroaryl C_{1-3} alkyl, C_{1-3} alkylene $N(R^a)_2$, C_{1-6} alkylene-aryl, C_{1-6} alkyleneHet, halo C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, Het, C_{1-3} alkyleneheteroaryl, C_{1-6} alkylene $C(=O)OR^a$, and C_{1-3} alkylene C_{3-8} heterocyclo-alkyl;

25 or R^b and R^c are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;

30 Het is a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C_{1-4} alkyl or $C(=O)OR^a$;

p is 0, 1, 2, or 3;

- 10 -

t is 1, 2, 3, or 4;
and pharmaceutically acceptable salts and
solvates (e.g., hydrates) thereof.

As used herein, the term "alkyl" includes
5 straight chained and branched hydrocarbon groups
containing the indicated number of carbon atoms,
typically methyl, ethyl, and straight chain and
branched propyl and butyl groups. The hydrocarbon
group can contain up to 16 carbon atoms. The term
10 "alkyl" includes "bridged alkyl," i.e., a C₆-C₁₆
bicyclic or polycyclic hydrocarbon group, for ex-
ample, norbornyl, adamantyl, bicyclo[2.2.2]octyl,
bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, or deca-
hydronaphthyl. The term "cycloalkyl" is defined as
15 a cyclic C₃-C₈ hydrocarbon group, e.g., cyclopropyl,
cyclobutyl, cyclohexyl, and cyclopentyl. "Hetero-
cycloalkyl" is defined similarly as cycloalkyl
except the ring contains one to three heteroatoms
selected from the group consisting of oxygen, nitro-
20 gen, and sulfur.

The term "alkenyl" is defined identically
as "alkyl," except for containing a carbon-carbon
double bond. "Cycloalkenyl" is defined similarly to
cycloalkyl, except a carbon-carbon double bond is
25 present in the ring.

The term "alkylene" refers to an alkyl
group having a substituent. For example, the term
"C₁₋₃alkylenearyl" refers to an alkyl group contain-
ing one to three carbon atoms, and substituted with
30 an aryl group. The term "alkenylene" as used herein
is similarly defined, and contains the indicated
number of carbon atoms and a carbon-carbon double

- 11 -

bond, and includes straight chained and branched alkenylene groups, like ethylenylene.

The term "halo" or "halogen" is defined herein to include fluorine, bromine, chlorine, and 5 iodine.

The term "haloalkyl" is defined herein as an alkyl group substituted with one or more halo substituents, either fluoro, chloro, bromo, iodo, or combinations thereof. Similarly, "halocycloalkyl" 10 is defined as a cycloalkyl group having one or more halo substituents.

The term "aryl," alone or in combination, is defined herein as a monocyclic or polycyclic aromatic group, preferably a monocyclic or bicyclic 15 aromatic group, e.g., phenyl or naphthyl. Unless otherwise indicated, an "aryl" group can be unsubstituted or substituted, for example, with one or more, and in particular one to three, halo, alkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, 20 amino, alkylamino, acylamino, alkylthio, $\text{NHC}(=\text{O})\text{C}_{1-3}-$ alkyl, $\text{OC}_{1-3}\text{alkyleneNR}^a\text{R}^b$, alkylsulfinyl, and alkylsulfonyl. Exemplary aryl groups include phenyl, naphthyl, tetrahydronaphthyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 4- 25 methoxyphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, and the like. The terms "aryl C_{1-3} alkyl" and "heteroaryl C_{1-3} alkyl" are defined as an aryl or heteroaryl group having a C_{1-3} alkyl substituent.

The term "heteroaryl" is defined herein as 30 a monocyclic or bicyclic ring system containing one or two aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring, and which can be unsubstituted or substituted,

- 12 -

for example, with one or more, and in particular one to three, substituents, like halo, alkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl. Examples of heteroaryl groups include thienyl, furyl, pyridyl, oxazolyl, quinolyl, isoquinolyl, indolyl, triazolyl, isothiazolyl, isoxazolyl, imidizolyl, benzothiazolyl, pyrazinyl, pyrimidinyl, thiazolyl, and thiadiazolyl.

The term "Het" is defined as a 5- or 6-membered heterocycle containing one or more heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur. A "Het" group also can contain an oxo group (=O) attached to the ring.

Nonlimiting examples of Het groups include 1,3-dioxolane, 2-pyrazoline, pyrazolidine, pyrrolidine, piperazine, a pyrrolidine, 2H-pyran, 4H-pyran, morpholine, thiopholine, piperidine, 1,4-dithiane, and 1,4-dioxane.

The term "hydroxy" is defined as -OH.

The term "alkoxy" is defined as -OR, wherein R is alkyl.

The term "alkoxyalkyl" is defined as an alkyl group wherein a hydrogen has been replaced by an alkoxy group. The term "(alkylthio)alkyl" is defined similarly as alkoxyalkyl, except a sulfur atom, rather than an oxygen atom, is present.

The term "hydroxyalkyl" is defined as a hydroxy group appended to an alkyl group.

The term "amino" is defined as -NH₂, and the term "alkylamino" is defined as -NR₂, wherein at least one R is alkyl and the second R is alkyl or hydrogen.

- 13 -

The term "acylamino" is defined as
 $RC(=O)N$, wherein R is alkyl or aryl.

The term "alkylthio" is defined as $-SR$,
 wherein R is alkyl.

5 The term "alkylsulfinyl" is defined as
 $R-SO_2$, wherein R is alkyl.

The term "alkylsulfonyl" is defined as
 $R-SO_3$, wherein R is alkyl.

The term "nitro" is defined as $-NO_2$.

10 The term "trifluoromethyl" is defined as
 $-CF_3$.


The term "trifluoromethoxy" is defined as
 $-OCF_3$.

15 The term "spiro" as used herein refers to
 a group having two carbon atoms directly bonded to
 the carbon atom to which R^1 is attached.

The term "cyano" is defined as $-CN$.

20 In a preferred embodiment, q is 0. In
 other preferred embodiments, R^0 is selected from the
 group consisting of C_{1-6} alkyl, aryl, heteroaryl, Het,
 OR^a , $C(=O)OR^a$, C_{1-4} alkyleneNR^aR^b, $OC(=O)R^a$, $C(=O)R^a$,
 NR^aR^b , C_{3-8} cycloalkyl, C_{3-8} cycloalkylQ, $C(=O)NR^aR^b$, and
 $C(=O)NR^bR^c$.

25 In a preferred group of compounds of
 formula (I), R^1 is represented by




30

wherein the bicyclic ring can represent,
 for example, naphthalene or indene, or a hetero-

- 14 -

cycle, such as benzoxazole, benzothiazole, benzisoxazole, benzimidazole, quinoline, indole, benzothiophene, or benzofuran, or


5



10 wherein m is an integer 1 or 2, and G, independently, is $C(R^a)_2$, O, S, or NR^a . The bicyclic ring comprising the R^1 substituent typically is attached to the rest of the molecule by a phenyl ring carbon atom.


15 In a more preferred group of compounds of formula (I), R^1 is represented by an optionally substituted bicyclic ring

20




25 wherein m is 1 or 2, and G, independently, are $C(R^a)_2$ or O. Especially preferred R^1 substituents include


- 15 -




10



15




25




30


- 16 -



5




10



15


20




25

30

- 17 -




5



10

, and




15


Within this particular group of compounds, nonlimiting examples of substituents for the aromatic ring include halogen (e.g., chlorine), C_{1-3} alkyl (e.g., 20 methyl, ethyl, or i-propyl), OR^a (e.g., methoxy, ethoxy, or hydroxy), CO_2R^a , halomethyl or halomethoxy (e.g., trifluoromethyl or trifluoromethoxy), cyano, $NR^aC(=O)R^a$, nitro, and NR^aR^b .

In other preferred embodiments, R^1 is 25 optionally substituted and selected from the group consisting of C_{1-4} alkyleneQR^a, C_{1-4} alkyleneQC₁₋₄alkyleneQR^a, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, C_{1-6} alkyl,


30




- 18 -



5



10




15

20


In a more preferred group of compounds of
formula (I), R¹ is represented by

25




30

- 19 -




5




10

15 C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, C_{1-6} alkyl, C_{1-4} alkyleneQR^a, and C_{1-4} alkyleneQC₁₋₄alkyleneQR^a. A preferred Q is oxygen.

Some preferred R¹ substituents are




20




25


- 20 -



5




10



15


-CH₂OR^a, -CH₂OCH₂OR^a

20



, and

25



30

- 21 -

Within this particular group of compounds, preferred R^a substituents include hydrogen, C₁₋₆alkyl, and benzyl.

5 In a preferred embodiment, R² is selected from the group consisting of hydrogen, aryl, heteroaryl, OR^a, NR^aR^b, NR^bR^c, C₁₋₄alkyleneHet, C₁₋₄alkylene-heteroaryl, C₁₋₄alkylenearyl, C₁₋₄alkyleneC(=O)C₁₋₄-alkylenearyl, C₁₋₄alkyleneC(=O)OR^a, C₁₋₄alkyleneC(=O)-NR^bR^c, C₁₋₄alkyleneC(=O)Het, C₁₋₄alkyleneNR^bR^c, C₁₋₄-alkyleneNR^aC(=O)R^a, and C₁₋₄alkyleneOC₁₋₄alkyleneOR^a.

10 In a more preferred embodiment, R² is hydrogen.

In preferred embodiments, R³ is hydrogen, C₁₋₆alkyl, aryl, or heteroaryl.

15 In preferred embodiments, Y is null, or is C(=O), C(=O)C≡C, C(=O)(CH₂)_t, SO₂, or C(=S).

In preferred embodiments, A is selected from the group consisting of




20 phenyl



25 furanyl


30

- 22 -




thienyl

5




pyrrolyl

10




oxazolyl

15




thiazolyl

20



imidazolyl


25



pyrazolyl


30

- 23 -




isoxazolyl

5




isothiazolyl

10




1, 2, 3-oxadiazolyl

15



1, 2, 3-triazolyl

20




1, 3, 4-thiadiazolyl

25


30

- 24 -




1, 2, 4-oxadiazolyl

5




1, 2, 5-oxadiazolyl

10




1, 3, 4-oxadiazolyl

15



1, 2, 3, 4-oxatriazolyl

20




1, 2, 3, 5-oxatriazolyl

25


30

- 25 -




pyridinyl

5




pyridazinyl

10




pyrimidinyl

15



pyrazinyl

20




1, 3, 5-triazinyl

25


30

- 26 -



5


1,2,4-triazinyl



10


1,2,3-triazinyl

15



indolizinyl


20



25


indolyl

30




isoindolyl

- 27 -



5


benzo (b) furanyl



10


benzothienyl

15




1H-indazolyl

20






25

benzimidazolyl




benzthiazonyl


- 28 -



4H-quinolizinyl




quinolinyl




isoquinolinyl

30

- 29 -



5 indenyl




10 naphthyl

15 R^4 is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, halo, $C(=O)OR^b$, $NHC(=O)C_{1-3}$ alkylene $N(R^b)_2$, NO_2 , $C(=O)OR^b$, OR^b , CF_3 , OR^a , CN , $OC(=O)R^b$, aryl OR^b , Het, $NR^aC(=O)C_{1-3}$ alkylene $C(=O)-OR^a$, aryl OC_{1-3} alkylene NR^aR^b , aryl $OC(=O)R^a$, C_{1-4} alkylene-
 20 $C(=O)OR^b$, OC_{1-4} alkylene $C(=O)OR^b$, $C(=O)NR^bSO_2R^c$, C_{1-4} -alkylene NR^bR^c , C_{2-6} alkenylene NR^bR^c , $C(=O)NR^bC_{1-4}$ alkylene OR^b , NR^bC_{1-4} alkylene NR^bR^c , $NR^bC(=O)R^c$, $NR^bC(=O)NR^bR^c$, OSO_2CF_3 , $C(=O)R^b$, C_{1-3} alkylenearyl, C_{1-4} alkyleneHet, C_{1-6} alkylene OR^b , C_{1-3} alkylene $N(R^b)_2$, NR^bR^c , $C(=O)NR^bR^c$,
 25 $NHC(=O)C_{1-C_3}$ alkylenearyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, $NHC(=O)C_{1-3}$ alkyleneHet, $NHC(=O)haloC_{1-6}$ -alkyl, and

30

- 30 -




10


In preferred embodiments, p is 0 or R^5 groups, independently, are selected from the group consisting of halo, oxo, C_{1-6} alkyl, NR^aR^b , or OR^a .

15 In especially preferred embodiments, q is 0 or R^6 is selected from the group consisting of halo, methyl, trifluoromethyl, and trifluoromethoxy; R^1 is selected from the group consisting of

20




25




30

- 31 -


5



10




15




20

25




30


- 32 -



5




10



15

, and



20


30

;


- 33 -

R² is selected from the group consisting of hydrogen, C₁₋₆alkyl, C(=O)NR^bR^c, and C₁₋₄alkyleneHet; R³ is selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl, and heteroaryl; Y is null, or Y is selected from the group consisting of C(=O), C(=O)C≡C, C(=O)CH₂, C(=O)CH₂CH₂, and SO₂; A is selected from the group consisting of


10




15



20




25




30


- 34 -




5




10



15




20



25

, and



30


;

R^4 is selected from the group consisting of H, $NHC(=O)CH_3$, $N(CH_3)_2$, $C(=O)NH_2$, $NHCH_3$, NO_2 , NH_2 , Br,


- 35 -

$\text{C}(\text{=O})\text{CH}_3$, OCH_3 , CH_2OCH_3 , $\text{NHC}(\text{=O})\text{CH}_2\text{N}(\text{CH}_3)_2$, $\text{CH}_2\text{N}(\text{CH}_3)_2$,
 CH_3 , Cl , $\text{NHC}(\text{=O})\text{CH}_2\text{CO}_2\text{H}$,

5




10



15





20









25

30


- 36 -




- 37 -




- 38 -




5



10




15




20

25




30


- 39 -



5



10



15

; and

20


p is 0 or R^5 groups, independently, are selected from the group consisting of CH_3 , Cl , oxo, and OCH_3 .

An especially preferred subclass of compounds within the general scope of formula (I) is represented by compounds of formula (III)

25

- 40 -

5



(III)

10

and pharmaceutically acceptable salts and solvates (e.g., hydrates) thereof.

15 Compounds of formula (I) can contain one or more asymmetric center, and, therefore, can exist as stereoisomers. The present invention includes both mixtures and separate individual stereoisomers of the compounds of formula (I). Compounds of formula (I) also can exist in tautomeric forms, and 20 the invention includes both mixtures and separate individual tautomers thereof.

Pharmaceutically acceptable salts of the compounds of formula (I) can be acid addition salts formed with pharmaceutically acceptable acids.

25 Examples of suitable salts include, but are not limited to, the hydrochloride, hydrobromide, sulfate, bisulfate, phosphate, hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulfonate, benzenesulfonate, and p-toluenesulfonate salts. The compounds of formula (I) also can provide pharmaceutically acceptable metal salts, in particular alkali metal salts and alkaline earth

- 41 -

metal salts, with bases. Examples include the sodium, potassium, magnesium, and calcium salts.

Compounds of the present invention are potent and selective inhibitors of cGMP-specific PDE5. Thus, compounds of formula (I) are of interest for use in therapy, specifically for the treatment of a variety of conditions where selective inhibition of PDE5 is considered to be beneficial.

Phosphodiesterases (PDEs) catalyze the hydrolysis of cyclic nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). The PDEs have been classified into at least seven isoenzyme families and are present in many tissues (J.A. Beavo, *Physiol. Rev.*, 75, p. 725 (1995)).

PDE5 inhibition is a particularly attractive target. A potent and selective inhibitor of PDE5 provides vasodilating, relaxing, and diuretic effects, all of which are beneficial in the treatment of various disease states. Research in this area has led to several classes of inhibitors based on the cGMP basic structure (E. Sybertz et al., *Expert. Opin. Ther. Pat.*, 7, p. 631 (1997)).

The biochemical, physiological, and clinical effects of PDE5 inhibitors therefore suggest their utility in a variety of disease states in which modulation of smooth muscle, renal, hemostatic, inflammatory, and/or endocrine function is desirable. The compounds of formula (I), therefore, have utility in the treatment of a number of disorders, including stable, unstable, and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, acute respiratory

- 42 -

distress syndrome, acute and chronic renal failure, atherosclerosis, conditions of reduced blood vessel patency (e.g., postpercutaneous transluminal coronary or carotid angioplasty, or post-bypass surgery graft stenosis), peripheral vascular disease, vascular disorders, such as Raynaud's disease, thrombocythemia, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, peptic ulcer, male erectile dysfunction, female sexual dysfunction, and diseases characterized by disorders of gut motility (e.g., irritable bowel syndrome).

An especially important use is the treatment of male erectile dysfunction, which is one form of impotence and is a common medical problem. Impotence can be defined as a lack of power, in the male, to copulate, and can involve an inability to achieve penile erection or ejaculation, or both. The incidence of erectile dysfunction increases with age, with about 50% of men over the age of 40 suffering from some degree of erectile dysfunction.

In addition, a further important use is the treatment of female arousal disorder. Female arousal disorders are defined as a recurrent inability to attain or maintain an adequate lubrication/swelling response of sexual excitement until completion of sexual activity. The arousal response consists of vasocongestion in the pelvis, vaginal lubrication, and expansion and swelling of external genitalia.

It is envisioned, therefore, that compounds of formula (I) are useful in the treatment of

- 43 -

5 male erectile dysfunction and female arousal disorder. Thus, the present invention concerns the use of compounds of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal and arousal disorder in a female animal, including humans.

10 The term "treatment" includes preventing, lowering, stopping, or reversing the progression or severity of the condition or symptoms being treated. As such, the term "treatment" includes both medical therapeutic and/or prophylactic administration, as 15 appropriate.

15 It also is understood that "a compound of formula (I)," or a physiologically acceptable salt or solvate thereof, can be administered as the neat compound, or as a pharmaceutical composition containing either entity.

20 Although the compounds of the invention are envisioned primarily for the treatment of sexual dysfunction in humans, such as male erectile dysfunction and female arousal disorder, they also can 25 be used for the treatment of other disease states.

25 A further aspect of the present invention, therefore, is providing a compound of formula (I) for use in the treatment of stable, unstable, and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, acute respiratory distress syndrome, acute and chronic renal failure, atherosclerosis, conditions of reduced blood vessel paten-

- 44 -

cy (e.g., post-PTCA or post-bypass graft stenosis), peripheral vascular disease, vascular disorders such as Raynaud's disease, thrombocythemia, inflammatory diseases, prophylaxis of myocardial infarction, 5 prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and female erectile dysfunction, or diseases characterized by disorders of gut 10 motility (e.g., IBS).

According to another aspect of the present invention, there is provided the use of a compound of formula (I) for the manufacture of a medicament for the treatment of the above-noted conditions and 15 disorders.

In a further aspect, the present invention provides a method of treating the above-noted conditions and disorders in a human or nonhuman animal body which comprises administering to said body a 20 therapeutically effective amount of a compound of formula (I).

Compounds of the invention can be administered by any suitable route, for example by oral, buccal, inhalation, sublingual, rectal, vaginal, 25 transurethral, nasal, topical, percutaneous, i.e., transdermal, or parenteral (including intravenous, intramuscular, subcutaneous, and intracoronary) administration. Parenteral administration can be accomplished using a needle and syringe, or using a 30 high pressure technique, like POWDERJECT™.

Oral administration of a compound of the invention is the preferred route. Oral administration is the most convenient and avoids the dis-

- 45 -

advantages associated with other routes of administration. For patients suffering from a swallowing disorder or from impairment of drug absorption after oral administration, the drug can be administered 5 parenterally, e.g., sublingually or buccally.

Compounds and pharmaceutical compositions suitable for use in the present invention include those wherein the active ingredient is administered in an effective amount to achieve its intended purpose. More specifically, a "therapeutically effective amount" means an amount effective to prevent 10 development of, or to alleviate the existing symptoms of, the subject being treated. Determination of the effective amounts is well within the capability of those skilled in the art, especially in 15 light of the detailed disclosure provided herein.

A "therapeutically effective dose" refers to that amount of the compound that results in achieving the desired effect. Toxicity and therapeutic efficacy of such compounds can be determined 20 by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 25 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD₅₀ and ED₅₀. Compounds which exhibit high therapeutic 30 indices are preferred. The data obtained from such data can be used in formulating a range of dosage for use in humans. The dosage of such compounds preferably lies within a range of circulating concentrations that include the ED₅₀ with little or no

- 46 -

toxicity. The dosage can vary within this range depending upon the dosage form employed, and the route of administration utilized.

The exact formulation, route of administration, and dosage can be chosen by the individual physician in view of the patient's condition. Dosage amount and interval can be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the therapeutic effects.

The amount of composition administered is dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration, and the judgment of the prescribing physician.

Specifically, for administration to a human in the curative or prophylactic treatment of the conditions and disorders identified above, oral dosages of a compound of formula (I) generally are about 0.5 to about 1000 mg daily for an average adult patient (70 kg). Thus, for a typical adult patient, individual tablets or capsules contain 0.2 to 500 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day. Dosages for intravenous, buccal, or sublingual administration typically are 0.1 to 500 mg per single dose as required. In practice, the physician determines the actual dosing regimen which is most suitable for an individual patient, and the dosage varies with the age, weight, and response of the particular patient. The above dosages are exemplary of the average case, but there can be individual instances in which higher or lower

- 47 -

dosages are merited, and such are within the scope of this invention.

For human use, a compound of the formula (I) can be administered alone, but generally is administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions for use in accordance with the present invention thus can be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries that facilitate processing of compounds of formula (I) into preparations which can be used pharmaceutically.

These pharmaceutical compositions can be manufactured in a conventional manner, e.g., by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen. When a therapeutically effective amount of a compound of the present invention is administered orally, the composition typically is in the form of a tablet, capsule, powder, solution, or elixir. When administered in tablet form, the composition can additionally contain a solid carrier, such as a gelatin or an adjuvant. The tablet, capsule, and powder contain about 5% to about 95% compound of the present invention, and preferably from about 25% to about 90% compound of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, or oils of animal or plant origin can be added. The liquid form of

- 48 -

the composition can further contain physiological saline solution, dextrose or other saccharide solutions, or glycols. When administered in liquid form, the composition contains about 0.5% to about 5 90% by weight of a compound of the present invention, and preferably about 1% to about 50% of a compound of the present invention.

When a therapeutically effective amount of a compound of the present invention is administered by intravenous, cutaneous, or subcutaneous injection, the composition is in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. 10 15 A preferred composition for intravenous, cutaneous, or subcutaneous injection typically contains, in addition to a compound of the present invention, an isotonic vehicle.

For oral administration, the compounds can be formulated readily by combining a compound of formula (I) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the present compounds to be formulated as tablets, 20 25 pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by adding a compound of formula (I) with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, for example,

- 49 -

fillers and cellulose preparations. If desired, disintegrating agents can be added.

For administration by inhalation, compounds of the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin, for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection can be presented in unit dosage form, e.g., in ampules or in multidose containers, with an added preservative. The compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing, and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension. Optionally, the suspension also can contain suitable

- 50 -

stabilizers or agents that increase the solubility of the compounds and allow for the preparation of highly concentrated solutions. Alternatively, a present composition can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

Compounds of the present invention also can be formulated in rectal compositions, such as suppositories or retention enemas, e.g., containing conventional suppository bases. In addition to the formulations described previously, the compounds also can be formulated as a depot preparation. Such long-acting formulations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Many of the compounds of the present invention can be provided as salts with pharmaceutically compatible counterions. Such pharmaceutically acceptable base addition salts are those salts that retain the biological effectiveness and properties of the free acids, and that are obtained by reaction with suitable inorganic or organic bases.

In particular, a compound of formula (I) can be administered orally, buccally, or sublingually in the form of tablets containing excipients, such as starch or lactose, or in capsules or ovules, either alone or in admixture with excipients, or in the form of elixirs or suspensions containing

- 51 -

flavoring or coloring agents. Such liquid preparations can be prepared with pharmaceutically acceptable additives, such as suspending agents. A compound also can be injected parenterally, for example, intravenously, intramuscularly, subcutaneously, or intracoronarily. For parenteral administration, the compound is best used in the form of a sterile aqueous solution which can contain other substances, for example, salts, or monosaccharides, such as mannitol or glucose, to make the solution isotonic with blood.

For veterinary use, a compound of formula (I) or a nontoxic salt thereof, is administered as a suitably acceptable formulation in accordance with normal veterinary practice. The veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal.

Thus, the invention provides in a further aspect a pharmaceutical composition comprising a compound of the formula (I), together with a pharmaceutically acceptable diluent or carrier therefor. There is further provided by the present invention a process of preparing a pharmaceutical composition comprising a compound of formula (I), which process comprises mixing a compound of formula (I), together with a pharmaceutically acceptable diluent or carrier therefor.


In a particular embodiment, the invention includes a pharmaceutical composition for the curative or prophylactic treatment of erectile dysfunction in a male animal, or arousal disorder in a female animal, including humans, comprising a com-

- 52 -

pound of formula (I) or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.


Compounds of formula (I) can be prepared
5 by any suitable method known in the art, or by the
following processes which form part of the present
invention. In the methods below, R^0 , R^1 , R^2 , R^3 , R^4 ,
and R^5 , as well as Y and A , are defined as in struc-
10 tural formula (I) above. For example, compounds of
structural formula (I) can be prepared according to
the following synthetic scheme, which comprises
reacting compounds of formulae (IV) and (V). This
type of reaction is described in Bombrun U.S. Patent
No. 6,117,881, incorporated herein by reference.

15



(IV)

25




(V)

30

- 53 -

5 The reaction is performed in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) and 1-hydroxybenzotriazole (HOBT) in a suitable organic solvent, such as dimethylformamide (DMF) or dichloromethane (CH₂Cl₂) for several hours, e.g., 8 hours to 2 days.

10 A compound of formula (IV) can be prepared by Pictet-Spengler cyclization between a tryptamine derivative of formula (VI) and an aldehyde of formula R¹CHO.



(VI)

20

25 The reaction can be performed in a suitable solvent such as a halogenated hydrocarbon (e.g., dichloromethane) or an aromatic hydrocarbon (e.g., toluene) in the presence of an acid, such as trifluoroacetic acid (TFA). The reaction can be performed at a temperature of 20°C to reflux to provide a compound of formula (IV) in one step. The reaction also can be carried out in a solvent, such as an aromatic hydrocarbon (e.g., toluene), under reflux, optionally using a Dean-Stark apparatus to trap the produced water.

- 54 -

The reaction provides racemic compounds of formula (IV). Enantiomers can be obtained from a resolution of N-acetyl leucine using fractional crystallization in EtOAc:MeOH (ethyl acetate:methanol) as the solvent. (R) and (S) enantiomers can be isolated as salts, depending upon whether N-acetyl-(D)- and -(L)-leucine was used as the starting material.

Compounds of formulae (VI) and R¹CHO are commercially available compounds or are prepared by standard synthetic techniques.

The following examples show other synthetic methods for the preparation of compounds of structural formula (I).

It should be understood that protecting groups can be utilized in accordance with general principles of synthetic organic chemistry to provide compounds of structural formula (I). Protecting group-forming reagents, like benzyl chloroformate and trichloroethyl chloroformate, are well known to persons skilled in the art, for example, see T.W. Greene et al., "Protective Groups in Organic Synthesis, Third Edition," John Wiley and Sons, Inc., NY, NY (1999). These protecting groups are removed when necessary by appropriate basic, acidic, or hydrolytic conditions known to persons skilled in the art. Accordingly, compounds of structural formula (I) not specifically exemplified herein can be prepared by persons skilled in the art.

In addition, compounds of formula (I) can be converted to other compounds of formula (I). Thus, for example, a particular R substituent can be interconverted to prepare another suitably substi-

- 55 -

tuted compound of formula (I). Examples of appropriate interconversions include, but are not limited to, OR^a to hydroxy by suitable means (e.g., using an agent such as BBr₃, or a palladium catalyst, like palladium-on-carbon, with hydrogen), or amino to substituted amino, such as acylamino or sulphonyl-amino, using standard acylating or sulfonylating conditions.

Compounds of formula (I) can be prepared by the method above as individual stereoisomers or as a racemic mixture. Individual stereoisomers of the compounds of the invention can be prepared from racemates by resolution using methods known in the art for the separation of racemic mixtures into their constituent stereoisomers, for example, using HPLC on a chiral column, such as Hypersil naphthyl urea, or using separation of salts of stereoisomers. Compounds of the invention can be isolated in association with solvent molecules by crystallization from, or evaporation of, an appropriate solvent.

The pharmaceutically acceptable acid addition salts of the compounds of formula (I) that contain a basic center can be prepared in a conventional manner. For example, a solution of the free base can be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts can be obtained in an analogous manner by treating a solution of a compound of formula (I) with a suitable base. Both types of salt can be formed or interconverted

- 56 -

using ion-exchange resin techniques. Thus, according to a further aspect of the invention, a method for preparing a compound of formula (I) or a salt or solvate (e.g., hydrate) is provided, followed by (i) 5 salt formation, or (ii) solvate (e.g., hydrate) formation.


The following additional abbreviations are used hereafter in the accompanying examples: rt (room temperature), min (minute), h (hour), g 10 (gram), mmol (millimole), m.p. (melting point), eq (equivalents), L (liter), mL (milliliter), μ L (microliter), saturated (sat.), DMSO (dimethyl sulfoxide), CH_2Cl_2 (dichloromethane), IPA (isopropyl alcohol), TFA (trifluoroacetic acid), EtOH (ethanol), MeOH (methanol), DMF (dimethylformamide), CHCl_3 (chloroform), NaOH (sodium hydroxide), Na_2SO_4 (sodium sulfate), Et_2O (diethyl ether), EtOAc (ethyl acetate), Na_2CO_3 (sodium carbonate), MgSO_4 (magnesium sulfate), iPr_2O (diisopropyl ether), NaHCO_3 (sodium 15 bicarbonate), Et_3N (triethylamine), AcOH (acetic acid), and THF (tetrahydrofuran). 20

- 57 -

Intermediate 1

1-Phenyl-2,3,4,9-tetrahydro-1H- β -carboline

5



10


A solution of tryptamine (15 g, 94.0 mmol) and benzaldehyde (10.9 g, 1.1 eq.) in CH_2Cl_2 (800 mL) was treated with TFA (15 mL, 2 eq.). The resulting mixture was stirred at room temperature (rt) for one day, then neutralized to pH 7 with a saturated aqueous solution of Na_2CO_3 . After filtration and concentration to dryness, the residue was recrystallized from IPA to give Intermediate 1 (11.0 g, 47%) as white crystals (m.p.: 175-177°C).

Intermediate 2

1-(3,4-Methylenedioxophenyl)-2,3,4,9-tetrahydro-1H- β -carboline

25

30



35


- 58 -

5 Intermediate 2 was prepared by the same procedure as Intermediate 1 using tryptamine (20.0 g, 120 mmol), 3,4-methylenedioxybenzaldehyde (20.6 g, 1.1 eq.) and TFA (18 mL, 2 eq.) to give Intermediate 2 (22 g, 60%) as white crystals after recrystallization from ethanol (m.p.: 178°C).

Intermediate 3

10 1-(2,3-Dihydrobenzofuran-5-yl)-2,3,4,9-tetrahydro-
1H-β-carboline

15



20

25

30 Intermediate 3 was prepared using a two-step procedure. A solution of tryptamine (32.4 g, 0.2 mol) and 2,3-dihydrobenzofuran-5-carboxaldehyde (30.0 g, 1 eq.) in toluene (1L) was heated under reflux for 4 hours. After removal of 4 mL of water and evaporation of toluene, the residue was dissolved in CH₂Cl₂ (1L) in the presence of TFA (31 mL, 2 eq.). The resulting mixture was stirred at rt for 35 16 hours. Then, 1L of a saturated aqueous solution of NaHCO₃ was added. After extraction with CH₂Cl₂ and drying over MgSO₄, the organic solution was evaporated *in vacuo*. Recrystallization from CH₂Cl₂/iPr₂O (2:30) gave the title compound as white crys-

- 59 -

tals in an 80% yield. ^1H NMR (CDCl_3), δ 7.6 (s, 1H), 7.5-7.6 (m, 1H), 7-7.3 (m, 5H), 6.7-6.75 (d, 1H), 5.1 (s, 1H), 4.5-4.6 (t, 2H), 3.3-3.45 (m, 1H), 3.05-3.2 (t, 3H), 2.7-3 (m, 2H).

5

Intermediate 4

(R)-1-(2,3-Dihydrobenzofuran-5-yl)-2,3,4,9-tetrahydro-1H- β -carboline

10

Resolution of the racemic Intermediate 3 was achieved using N-acetyl-(D)-leucine (Sigma) in MeOH:EtOAc followed by recrystallization from MeOH. The suspension of the recrystallized material in CH_2Cl_2 was treated with a sat. aqueous NaHCO_3 to give the enantiomerically pure Intermediate 4 in 55% yield (m.p.: 98-99°C).

Analysis for $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O} \cdot 0.15 \text{ H}_2\text{O}$:

Calculated: C, 77.87; H, 6.29; N, 9.56

20

Found: C, 77.83; H, 6.33; N, 9.44

$[\alpha]_D^{21} = +42^\circ$ (c = 0.5, MeOH).

25


Intermediates 5 and 6 were prepared from Intermediate 2 and the appropriate carboxylic acid or acid chloride. Intermediate 7 was prepared from benzylamine and terephthalic acid.

- 60 -

Intermediate 5

(E)-1-(1-Benzo[1,3]dioxol-5-yl-1,3,4-tetrahydro- β -carbolin-2-yl)-3-(2-nitrophenyl)propenone

5



20

Intermediate 6


4-[1-(1-Benzo[1,3]dioxol-5-yl-1,3,4-tetrahydro- β -carbolin-2-yl)methanoyl]benzoic acid methyl ester

25

30

35


40



- 61 -

Intermediate 7N-Benzylterephthalamic acid

5




10

Example 11- (2H-Benzo[d]1,3-dioxolan-5-yl) (1,2,3,4-tetrahydro- β -carboline-2-yl)-2-naphthyl ketone

15

20



25

30


Naphthalene-2-carbonyl chloride was added to Intermediate 2 to provide Example 1 in 75% yield:
 35 mp 248-249°C. ^1H NMR (DMSO- d_6) δ : 11.1 (s, 0.2H), 11.08 (s, 0.8H), 8.06-7.95 (m, 2H), 7.74-7.24 (m, 7H), 7.15-6.76 (m, 6H), 6.15 (s, 2H), 3.47-3.17 (m, 2H), 2.85-2.40 (m, 2H); MS ES+ m/e 447 (p+1), ES- m/e 445 (m-1); IR (KBr, cm^{-1}): 3282, 1617, 1633.

- 62 -

Example 2

1- (2H-benzo[d]1,3-dioxolan-5-yl) (1R) (1,2,3,4-tetrahydro-β-carbolin-2-yl)2-naphthyl ketone

5



10

15

20

25

Naphthalene-2-carbonyl chloride was added to the (1R) stereoisomer of Intermediate 2 to provide Example 2 in 74% yield. mp 285°C. ¹H NMR (DMSO-d₆) δ: 11.1 (s, 0.2H), 11.08 (s, 0.8H), 8.06-7.95 (m, 2H), 7.74-7.24 (m, 7H), 7.15-6.76 (m, 6H), 6.15 (s, 2H), 3.47-3.17 (m, 2H), 2.85-2.40 (m, 2H); MS ES+m/e 447 (p+1), ES-m/e 445 (p-1); IR (KBr, cm⁻¹): 3282, 1617, 1633; 100% ee.


30

- 63 -

Example 3

1- (1-Benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl) -1-phenylmethanone

5



10

15

20

25

30

Intermediate 2 (0.68 mole, 200 mg) was reacted with benzoyl chloride (1.5 eq.) and NaHCO₃ (1.1 eq.) in CH₂Cl₂ by stirring the reaction mixture at room temperature. The reaction was quenched with aqueous sat. NaHCO₃. The resulting mixture was extracted with CH₂Cl₂, and the organic phase was dried. After filtering and removing the solvent by evaporation, Example 3 was purified by flash chromatography, eluting with CH₂Cl₂. The product was recrystallized from EtOH/CH₂Cl₂ (3/1) to provide Example 3 as white crystals. (m.p. 260-261°C), m.w. 396.45 (C₂₅H₂₀N₂O₃).


- 64 -

Example 4

N-[4-[1-(1-Benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carboline-2-yl)-methanoyl]phenyl]acetamide

5

10



15

20

Intermediate 2 was reacted with 4-acetamidobenzoic acid in CH_2Cl_2 in the presence of EDCI and Et_3N . The reaction product was isolated and purified by flash chromatography, eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (98:2). Recrystallization from ethanol yielded Example 4 as a white solid. m.p. 186-188°C, m.w. 453.5 ($\text{C}_{27}\text{H}_{23}\text{N}_3\text{O}_4$).


30

- 65 -

Example 5

1- (1-Benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)-1-(4-methylaminophenyl)methanone

5



10

15

20

25


Intermediate 2 was reacted with 4-(methylamino)benzoic acid in CH_2Cl_2 in the presence of EDCI and Et_3N . The reaction product was isolated and purified. Recrystallization yielded Example 5 as a white solid. m.w. 425.45 ($\text{C}_{26}\text{H}_{23}\text{N}_3\text{O}_3$).

30

Example 6

1- (1-Benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)-1-(4-dimethylaminophenyl)methanone

35



40


- 66 -

Intermediate 2 was reacted with 4-(dimethylamino)benzoic acid in CH_2Cl_2 in the presence of EDCI and Et_3N . The reaction product was isolated and purified. Recrystallization from CH_2Cl_2 yielded Example 6 as a white solid. m.w. 439.12 ($\text{C}_{27}\text{H}_{25}\text{N}_3\text{O}_3$).

5 **Example 7**

10 **4-[1-(1-Benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)methanoyl]benzamide**

15
20
25



30 Intermediate 6 was dissolved in 100 mL of CH_3OH , then reacted with ammonia at 35°C for about 2 hours. The CH_3OH was evaporated, and the residue was extracted with CH_2Cl_2 , followed by washing with brine. After drying, the CH_2Cl_2 was removed to yield Example 7. m.w. 439.47 ($\text{C}_{26}\text{H}_{21}\text{N}_3\text{O}_4$).


35

- 67 -

Example 8

1- (1-Benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl) -3-phenylpropynone

5



20

Intermediate 2 was reacted with 3-phenyl-propyne carboxylic acid in CH_2Cl_2 , in the presence of HOBT, EDCI, and Et_3N . The reaction product was isolated and purified by flash chromatography, eluting with CH_2Cl_3 . Recrystallization from EtOH yielded Example 8 as a white solid. m.p. 145.6°C, m.w. 420.47 ($\text{C}_{27}\text{H}_{20}\text{N}_2\text{O}_3$).

25


- 68 -

Example 9

3 - (2 - Aminophenyl) - 1 - (1 - benzo[1,3]dioxol - 5 - yl - 1,3,4,9 - tetrahydro - β - carbolin - 2 - yl) propan - 1 - one

5

10



15

Intermediate 5 was hydrogenated in the presence of a Pd/C (palladium on carbon) catalyst in a 50/50 mixture of EtOH/THF. The reaction was allowed to proceed for four hours, followed by filtering of the Pd/C catalyst from the reaction mixture, and removing the solvents by evaporation. The resulting product was extracted with CH_2Cl_2 , which then was removed by evaporation. The reaction product was purified by chromatography, eluting with CH_2Cl_2 . The product was recrystallized from a water/IPA solution to yield Example 9 as a white solid. (m.p. 214°C), m.w. 439.52 ($\text{C}_{27}\text{H}_{25}\text{N}_3\text{O}_3$).


- 69 -

Example 10

N-{4-[1-(1-Benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)methanoyl]phenyl}-2-phenylacetamide

5

10



15

Intermediate 2 was reacted with Intermediate 7 in CH_2Cl_2 , in the presence of HOBT, EDCI, and Et_3N . The reaction product was isolated and purified by flash chromatography, eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (95:5). Recrystallization from EtOH - water yielded Example 10 as a white solid. (m.p. 20 151-152°C), m.w. 529.60 ($\text{C}_{33}\text{H}_{27}\text{N}_3\text{O}_4$).


- 70 -

Example 11

1- (1-Benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl) -3-phenylpropan-1-one

5

10



15

20

Intermediate 2 was reacted with 3-phenyl-propanoic acid in CH_2Cl_2 in the presence of EDCI, HOBT, and Et_3N . The reaction product was isolated and purified. Recrystallization from CH_3OH yielded Example 11 as a white solid. m.w. 424.50 ($\text{C}_{27}\text{H}_{21}\text{N}_2\text{O}_3$).


- 71 -

Example 12

1- (1-Benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)-1-(3H-benzimidazol-5-yl)methanone

5

10



15


To a solution of Intermediate 2 (0.20 g., 0.68 mmol) and CH₂Cl₂ (100 mL) was added 5-benzimidazole carboxylic acid (0.12 g, 1.1 eq.), HOBT (0.12 g, 1.1 eq.), EDCI (0.14 g. 1.1 eq.), and Et₃N (0.10 mL, 1.1 eq.) at 25°C. After stirring at rt until the reaction was complete, the reaction mixture was quenched with water (20 mL). The quenched reaction mixture was extracted with CH₂Cl₂, then the organic layer was washed with brine and dried over MgSO₄. The solvent was removed *in vacuo*, then the residue was purified by flash chromatography, eluting with CH₂Cl₂/MeOH (95:5). Recrystallization from EtOH yielded Example 12 as white crystals. m.w. 438.47 (C₂₆H₂₀N₄O₃).

Examples 13-22 were prepared in a manner similar to Example 1-12. Example 23 further illus-

- 72 -


trates the preparation of compounds of the present invention.

Example 13a



5

Example 13b




10

- 73 -

Example 14

5




10

Example 15

15


20



- 74 -

Example 16

5




10

Example 17

15


20



- 75 -

Example 18

5




10

Example 19

15

20



25


30

- 76 -

Example 20

5


10

Example 21

15

20


25



- 77 -

Example 22

5



10


Example 23

15

2-Benzo [b] thiophen-3-yl-1-(1-benzo [1,3] dioxol-5-yl-1,3,4,9-tetrahydro-β-carbolin-2-yl)ethanone

20

25



30


Intermediate 2 was reacted with 3-benzo-thiophene carboxylic acid in CH_2Cl_2 , in the presence of HOBT, EDCI, and Et_3N . The reaction product was isolated and purified by flash chromatography, eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (90:10). Recrystallization from

- 78 -


iPr₂O yielded Example 23 as a white solid. m.w.
466.56 (C₂₈H₂₂N₂O₃S).

5 The following Examples 24-44 were prepared
by synthetic procedures similar to the procedures
used to prepare Examples 1-23.

Example 24




20 **Example 25**



- 79 -

Example 26


5



10


Example 27

15



- 80 -


Example 28



Example 29

5


10



15

- 81 -

Example 30




Example 31

5

10


15



- 82 -

Example 32


5



10

Example 33

15




20

- 83 -

Example 34

5




10

Example 35

15

20




25

- 84 -

Example 36


5



10

Example 37

15




20

- 85 -

Example 38

5




10

Example 39

15


20



- 86 -

Example 40


5



10

Example 41

15




20

25

- 87 -

Example 42

5




10

Example 43

15

20


25



- 88 -

Example 44

5



10


Example 45

15

2-[(1-(2H-benzo[d]1,3-dioxolan-5-yl)-1R-(1,2,3,4-tetrahydro-β-carolin-2-yl)sulfonyl]-5-chloro-3-methylbenzo[b]thiophene

20

25



30

(5-Chloro-3-methylbenzothiophen-2-yl)-sulfonyl chloride was added to Intermediate 2 to provide Example 45 in 46% yield. mp 139-143°C.
 NMR (DMSO-d₆) δ: 10.9 (s, 1H), 8.03 (d, J=8.8 Hz, 1H), 7.93 (s, 1H), 7.53 (dd, J=2.0, 8.7 Hz, 1H),


- 89 -

7.30 (m, 2H), 7.09 (m, 1H), 6.85-6.95 (m, 2H), 6.70
(s, 1H), 6.62 (dd, J=1.5, 8.0 Hz), 6.25 (s, 1H),
6.00 (s, 1H), 5.99 (s, 1H), 4.05 (dd, J=5.3, 14.5
Hz, 1H), 3.38-3.40 (m, 1H), 2.70 (dd, J=3.8, 16 Hz),
5 2.41-2.44 (m, 1H), 2.40 (s, 3H); MS ES+m/e 537.1
(p+1) E/S-m/e 535.1 (p-1).

Example 46

10 2-(1-Benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -
carbolin-2-yl)-6,7-dimethoxy-3H-quinazolin-4-one

15



20


25

Example 46 was prepared from Intermediate
2 and the quinazoline Intermediate 8 by the follow-
ing synthetic procedure. Intermediate 8 was pre-
pared in accordance with the procedure set forth in
J. Miller et al., *J. Med. Chem.*, 28, p. 12 (1985).


- 90 -

Quinazolinone Intermediate 8

5



10




15

Intermediate 8

A solution of 2,4-dichloro-6,7-dimethoxy-quinazoline (2.12 g, 8.20 mmol) in 1 M NaOH (50 mL) and THF (15 mL) was stirred at room temperature under an argon blanket for 23 hours. The solution was cooled to 0°C, then acidified to pH 5 with AcOH. The resulting solids were collected by vacuum filtration and dried in a vacuum oven at 70°C overnight to provide Intermediate 8 as a pale yellow powder (2.02 g, 100%). ¹H NMR (300 MHz, DMSO-d₆) δ: 7.38 (s, 1H), 7.08 (s, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.50-3.20 (br s, 1H).

- 91 -

Preparation of Example 46



A suspension of Intermediate 2 (3.26 g, 11.2 mmol) and Intermediate 2 (1.69 g, 7.0 mmol) in EtOH (25 mL) was heated in a sealed tube at 110°C for 2 days. The resulting solids were collected by vacuum filtration, then dissolved in EtOAc (100 mL). The mixture was washed with 1 M NaOH (100 mL), water (100 mL), and brine (100 mL), dried over Na₂SO₄, and filtered. The solvent was removed under reduced pressure to provide a yellow foam which was purified by flash column chromatography, eluting with EtOAc/-CH₂Cl₂/MeOH (1:4:0.1), to provide the crude product as a yellow solid. This crude product was purified by a slurry in Et₂O/MeOH, followed by vacuum filtration to provide Example 46 as a white solid (1.03 g, 33%): mp 282-290°C; TLC R_f (4:1:0.1 CH₂Cl₂/EtOAc/-MeOH=0.36. ¹H NMR (300 MHz, DMSO-d₆) δ: 11.46 (s, 1H), 10.99 (s, 1H), 7.46 (d, J=7.53 Hz, 1H), 7.32-7.28 (m, 2H), 7.10-6.96 (m, 3H), 6.88-6.71 (m, 4H), 5.98 (d, J=3.74 Hz, 2H), 4.46 (m, 1H), 3.86 (s, 3H), 3.79 (s, 3H), 3.40-3.30 (m, 2H), 2.87-2.74 (m, 2H); API MS m/z 497 [C₂₈H₂₄N₄P₅+H]⁺. Anal. Calcd. for C₂₈H₂₄N₄O₅: C, 67.73; H, 4.87; N, 11.28. Found: C, 67.53; H, 5.08; N, 11.12.

- 92 -

Example 47a

1-Benzo[1,3]dioxol-5-yl-2-(4-chloro-6,7-dimethoxy-quinazolin-2-yl)-2,3,4,9-tetrahydro-1H-β-carboline

5


Example 47b

1-Benzo[1,3]dioxol-5-yl-2-(6,7-dimethoxyquinazolin-2-yl)-2,3,4,9-tetrahydro-1H-β-carboline

10

Examples 47a and 47b were prepared from Example 46 by the following synthetic sequence.


15



20

25

- 93 -



Preparation of Example 47a

5 Phosphorous oxychloride (0.41 mL, 4.4 mmol) was added slowly to a slurry of Example 46 (0.73 g, 1.5 mmol) and Et₃N (0.41 mL, 2.9 mmol) in 1,4-dioxane (10 mL), and the mixture was heated at 100°C for 3 hours. The cooled reaction mixture was dissolved in CHCl₃ (100 mL), poured into ice water and neutralized with 2M NaOH. The organic layer was collected, washed with water (100 mL), and brine (100 mL), dried over Na₂SO₄, and concentrated under reduced pressure to provide an orange oil. This residue was purified by flash column chromatography, eluting with hexanes/EtOAc (2:1), to provide Example 47a as a yellow foam (0.80 g, 100%). A sample of Example 47a was further purified by a slurry in CH₂Cl₂, followed by vacuum filtration to provide a pale yellow solid which was dried overnight under vacuum at 85°C: mp 231/234°C; TLC R_f (2:1 hexanes/-ethyl acetate)=0.49. ¹H NMR (300 MHz, DMSO-d₆) δ: 10.98 (s, 1H), 7.46 (d, J=7.7 Hz, 1H), 7.31 (d,

10

15

20

- 94 -

J=7.8 Hz, 1H), 7.17 (s, 1H), 7.10-6.97 (m, 3H), 6.90-6.86 (m, 2H), 6.79 (d, J=7.9 Hz, 1H), 5.97 (d, J=4.4 Hz, 2H), 4.93-4.89 (m, 1H), 3.95 (s, 3H), 3.88 (s, 3H), 3.27-3.23 (m, 2H), 2.86-2.85 (m, 2H) ppm; 5 API MS m/z 515 [C₂₈H₂₃ClN₄O₄+H]⁺. Anal. Calcd. for C₂₈H₂₃ClN₄O₄: C, 65.31; H, 4.50; N, 10.88. Found: C, 64.92; H, 4.50; N, 10.79.

Preparation of Example 47b

10


A mixture of Example 47a (0.52 g, 1.01 mmol), a catalytic amount of 10% palladium on activated carbon (0.32 g, 10% wet), and concentrated ammonium hydroxide (1.5 mL) in EtOH (55 mL) was 15 stirred under a hydrogen atmosphere for 12 hours at room temperature. The palladium catalyst was removed by vacuum filtration through a plug of Celite, and the resulting filtrate was concentrated under reduced pressure and purified by flash column chromatography, eluting with hexanes/EtOAc (2:1), to provide the crude product. This crude product was further purified by trituration with a hexane/Et₂O/-CH₂Cl₂ mixture to provide Example 47b as a pale 20 yellow solid (0.21 g, 44%): mp 201-204°C; TLC R_f (2:1 hexanes/EtOAc)=0.26. ¹H NMR (300 MHz, DMSO-d₆) δ: 10.98 (s, 1H), 9.02 (s, 1H), 7.45 (d, J=7.6 Hz, 1H), 7.31 (d, J=7.9 Hz, 1H), 7.24-7.22 (m, 2H), 7.09-6.76 (m, 5H), 5.97 (d, J=4.8 Hz, 2H), 5.04-4.99 (m, 1H), 3.93 (s, 3H), 3.84 (s, 3H), 3.27-3.21 (m, 2H), 2.86-2.82 (m, 2H) ppm; API MS m/z 481 [C₂₈H₂₄N₄O₄+H]⁺. Anal. Calcd. for C₂₈H₂₄N₄O₄: C, 69.99; H, 5.03; N, 11.66. Found: C, 69.62; H, 5.13; N, 11.26.

- 95 -


The following Examples 48-87 were prepared by synthetic procedures analogous to the procedures used to synthesize Examples 1-47.

5

Example 48




Example 49



- 96 -

Example 50


5



10

Example 51


15



20

Example 52

25




30

- 97 -

Example 53

5




10

Example 54

15

20




25

- 98 -

Example 55

5




10

Example 56

15

20


25



- 99 -

Example 57

5




10

Example 58

15

20


25



- 100 -

Example 59

5




10

Example 60

15

20


25



- 101 -

Example 61

5




10

Example 62

15

20




25

- 102 -

Example 63

5




10

Example 64

15

20


25



- 103 -

Example 65

5




10

15

Example 66

20


25



- 104 -

Example 67

5




10

Example 68

15

20




25

- 105 -

Example 69


5



10

Example 70


15



- 106 -

Example 71

5




10

Example 72

15

20




25

- 107 -

Example 73

5




10

Example 74

15

20




25

- 108 -

Example 75

5




10

Example 76

15

20




25

- 109 -

Example 77

5




10

Example 78

15

20




25

- 110 -

Example 79

5




10

Example 80

15

20


25



- 111 -

Example 81


5



10

Example 82

15




20

- 112 -

Example 83

5




10

Example 84

15

20




25

30

- 113 -

Example 85


5



10

Example 86

15



20


25

30

- 114 -

Example 87

5



10

Compounds of the present invention can be
15 formulated into tablets for oral administration.

For example, a compound of formula (I) can be formed
into a dispersion with a polymeric carrier by the
coprecipitation method set forth in WO 96/38131,
incorporated herein by reference. The coprecipi-
20 tated dispersion then can be blended with excipi-
ents, then pressed into tablets, which optionally
ents, then pressed into tablets, which optionally
are film-coated.

The compounds of structural formula (I)
were tested for an ability to inhibit PDE5. The
ability of a compound to inhibit PDE5 activity is
25 related to the IC_{50} value for the compound, i.e., the
concentration of inhibitor required for 50% inhibi-
tion of enzyme activity. The IC_{50} value for com-
pounds of structural formula (I) were determined
30 using recombinant human PDE5.

The compounds of the present invention
typically exhibit an IC_{50} value against recombinant
human PDE5 of less than about 50 μ M, and preferably

- 115 -

less than about 25 μM , and more preferably less than about 15 μm . The compounds of the present invention typically exhibit an IC_{50} value against recombinant human PDE5 of less than about 1 μM , and often less than about 0.05 μM . To achieve the full advantage of the present invention, a present PDE5 inhibitor has an IC_{50} of about 0.1 nM to about 15 μM .

5 The production of recombinant human PDEs and the IC_{50} determinations can be accomplished by 10 well-known methods in the art. Exemplary methods are described as follows:

EXPRESSION OF HUMAN PDEs

15 Expression in *Saccharomyces cerevisiae* (Yeast)

Recombinant production of human PDE1B, PDE2, PDE4A, PDE4B, PDE4C, PDE4D, PDE5, and PDE7 was carried out similarly to that described in Example 7 20 of U.S. Patent No. 5,702,936, incorporated herein by reference, except that the yeast transformation vector employed, which is derived from the basic ADH2 plasmid described in Price et al., *Methods in Enzymology*, 185, pp. 308-318 (1990), incorporated 25 yeast ADH2 promoter and terminator sequences and the *Saccharomyces cerevisiae* host was the protease-deficient strain BJ2-54 deposited on August 31, 1998 with the American Type Culture Collection, Manassas, Virginia, under accession number ATCC 74465. Transformed host cells were grown in 2X SC-leu medium, pH 30 6.2, with trace metals, and vitamins. After 24 hours, YEP medium-containing glycerol was added to a final concentration of 2X YET/3% glycerol. Approx-

- 116 -

mately 24 hr later, cells were harvested, washed, and stored at -70°C.

HUMAN PHOSPHODIESTERASE PREPARATIONS

5

Phosphodiesterase Activity Determinations

Phosphodiesterase activity of the preparations was determined as follows. PDE assays utilizing a charcoal separation technique were performed essentially as described in Loughney et al. (1996). In this assay, PDE activity converts [³²P]cAMP or [³²P]cGMP to the corresponding [³²P]5'-AMP or [³²P]5'-GMP in proportion to the amount of PDE activity present. The [³²P]5'-AMP or [³²P]5'-GMP then was quantitatively converted to free [³²P]phosphate and unlabeled adenosine or guanosine by the action of snake venom 5'-nucleotidase. Hence, the amount of [³²P]phosphate liberated is proportional to enzyme activity. The assay was performed at 30°C in a 100 μ L reaction mixture containing (final concentrations) 40 mM Tris HCl (pH 8.0), 1 μ M ZnSO₄, 5 mM MgCl₂, and 0.1 mg/mL bovine serum albumin (BSA). PDE enzyme was present in quantities that yield <30% total hydrolysis of substrate (linear assay conditions). The assay was initiated by addition of substrate (1 mM [³²P]cAMP or cGMP), and the mixture was incubated for 12 minutes. Seventy-five (75) μ g of *Crotalus atrox* venom then was added, and the incubation was continued for 3 minutes (15 minutes total). The reaction was stopped by addition of 200 μ L of activated charcoal (25 mg/mL suspension in 0.1 M NaH₂PO₄, pH 4). After centrifugation (750 X g for

- 117 -

3 minutes) to sediment the charcoal, a sample of the supernatant was taken for radioactivity determination in a scintillation counter and the PDE activity was calculated.

5

Purification of PDE5 from *S. cerevisiae*

Cell pellets (29 g) were thawed on ice with an equal volume of Lysis Buffer (25 mM Tris HCl, pH 8, 5 mM MgCl₂, 0.25 mM DTT, 1 mM benzamidine, and 10 μ M ZnSO₄). Cells were lysed in a Microfluidizer[®] (Microfluidics Corp.) using nitrogen at 20,000 psi. The lysate was centrifuged and filtered through 0.45 μ m disposable filters. The filtrate was applied to a 150 mL column of Q SEPHAROSE[®] Fast-Flow (Pharmacia). The column was washed with 1.5 volumes of Buffer A (20 mM Bis-Tris Propane, pH 6.8, 1 mM MgCl₂, 0.25 mM DTT, 10 μ M ZnSO₄) and eluted with a step gradient of 125 mM NaCl in Buffer A followed by a linear gradient of 125-1000 mM NaCl in Buffer A. Active fractions from the linear gradient were applied to a 180 mL hydroxyapatite column in Buffer B (20 mM Bis-Tris Propane (pH 6.8), 1 mM MgCl₂, 0.25 mM DTT, 10 μ M ZnSO₄, and 250 mM KCl). After loading, the column was washed with 2 volumes of Buffer B and eluted with a linear gradient of 0-125 mM potassium phosphate in Buffer B. Active fractions were pooled, precipitated with 60% ammonium sulfate, and resuspended in Buffer C (20 mM Bis-Tris Propane, pH 6.8, 125 mM NaCl, 0.5 mM DTT, and 10 μ M ZnSO₄). The pool was applied to a 140 mL column of SEPHACRYL[®] S-300 HR and eluted with Buffer C.

- 118 -

Active fractions were diluted to 50% glycerol and stored at -20°C.

The resultant preparations were about 85% pure by SDS-PAGE. These preparations had specific activities of about 3 μ mol cGMP hydrolyzed per minute per milligram protein.

Inhibitory Effect on cGMP-PDE

cGMP-PDE activity of compounds of the present invention was measured using a one-step assay adapted from Wells et al., *Biochim. Biophys. Acta*, 384, 430 (1975). The reaction medium contained 50 mM Tris-HCl, pH 7.5, 5 mM magnesium acetate, 250 μ g/ml 5'-Nucleotidase, 1 mM EGTA, and 0.15 μ M 8-[H^3]-cGMP. Unless otherwise indicated, the enzyme used was a human recombinant PDE5 (ICOS Corp., Bothell, Washington).

Compounds of the invention were dissolved in DMSO finally present at 2% in the assay. The incubation time was 30 minutes during which the total substrate conversion did not exceed 30%.

The IC_{50} values for the compounds examined were determined from concentration-response curves typically using concentrations ranging from 10 nM to 10 μ M. Tests against other PDE enzymes using standard methodology showed that compounds of the invention are selective for the cGMP-specific PDE enzyme.

- 119 -

Biological Data

The compounds according to the present invention were typically found to exhibit an IC₅₀ value of less than 500 nM (i.e., 0.5 μ M). *In vitro* test data for representative compounds of the invention is given in the following table:

Table 1: *In vitro* Results

Example	PDE5 IC ₅₀ (μ M)
1	0.566
2	0.71
3	0.44 ¹⁾
4	0.05 ¹⁾
5	0.2
6	0.67
7	0.55
8	0.19
9	0.44
10	0.76
11	0.44
12	0.18 ¹⁾
13a	0.48
13b	0.02
14	0.2 ¹⁾
15	0.001 ¹⁾
16	0.07 ¹⁾
17	0.25 ¹⁾
18	0.11

- 120 -

Table 1: *In vitro* Results

Example	PDE5 IC ₅₀ (μM)
19	0.25
20	0.42
21	0.13
22	0.08
5 23	0.36
24	0.03
25	0.04
26	0.9
27	0.04
10 28	0.12
29	0.3
30	0.06
31	0.04
15 32	0.48
33	0.2
34	0.46
35	0.41
36	0.11
20 37	0.04
38	0.03
39	0.4
40	0.32
41	0.24
25 42	0.85
43	0.29
44	0.49
45	0.22

- 121 -

Table 1: *In vitro* Results

Example	PDE5 IC ₅₀ (μM)
46	0.005
47a	0.027
47b	0.005
48	0.02
5 49	0.01
50	0.78
51	0.03
52	0.29
53	0.07
10 54	0.56
55	0.02
56	0.04
57	0.06
58	0.03
15 49	0.04
60	0.07
61	0.04
62	0.05
63	0.04
20 64	0.76
65	0.02
66	0.34
67	0.07
68	0.02
25 69	0.009
70	0.02
71	0.02

- 122 -

Table 1: *In vitro* Results

Example	PDE5 IC ₅₀ (μM)
72	0.01
73	0.03
74	0.04
75	0.007
5 76	0.01
77	0.004
78	0.06
79	0.004
10 80	0.05
81	0.003
82	0.005
83	0.082
84	0.309
15 85	0.835
86	0.90
87	1.01

¹⁾ versus bovine aorta.

20


Obviously, many modifications and variations of the invention as hereinbefore set forth can be made without departing from the spirit and scope thereof, and, therefore, only such limitations should be imposed as are indicated by the appended claims.

25

- 123 -


WHAT IS CLAIMED IS:

1. A compound having a formula






wherein R⁰, independently, is selected from the group consisting of halo, C₁₋₆alkyl, aryl, heteroaryl, C₃₋₈cycloalkyl, C₃₋₈heterocycloalkyl, C₃₋₈cycloalkylQ, C(=O)R^a, OC(=O)R^a, C(=O)OR^a, C₁₋₄alkyleneNR^aR^b, C₁₋₄alkyleneHet, C₁₋₄alkyleneC(=O)OR^a, C(=O)NR^aSO₂R^c, C(=O)C₁₋₄alkyleneHet, C(=O)NR^aR^b, C(=O)NR^bR^c, C(=O)-NR^aC₁₋₄alkyleneOR^b, C(=O)NR^aC₁₋₄alkyleneHet, OR^a, OC₁₋₄-alkyleneC(=O)OR^a, OC₁₋₄alkyleneNR^aR^b, OC₁₋₄alkyleneHet, OC₁₋₄alkyleneOR^a, OC₁₋₄alkyleneNR^aC(=O)OR^b, NR^aR^b, NR^bR^c, NR^aC₁₋₄alkyleneNR^aR^b, NR^aC(=O)R^b, NR^aC(=O)NR^aR^b, N(SO₂C₁₋₄alkyl)₂, NR^a(SO₂C₁₋₄alkyl), nitro, trifluoromethyl, trifluoromethoxy, cyano, SO₂NR^aR^b, SO₂R^a, SOR^a, SR^a, and OSO₂CF₃;

R¹ is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, an optionally substituted C₃₋₈cycloalkyl ring, an optionally substituted C₃₋₈heterocycloalkyl ring, an optionally substituted bicyclic ring




- 124 -

wherein the fused ring B is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one to three heteroatoms selected from oxygen, sulfur, and nitrogen, hydrogen, C_{1-6} alkyl, aryl C_{1-3} alkyl, C_{1-3} -alkenylenearyl, halo C_{1-6} alkyl, C_{1-4} alkyleneC(=O)OR^a, C_{1-4} alkyleneC(=O)NR^aR^b, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, C_{3-8} heterocycloalkenyl, C_{1-4} alkyleneHet, C_{1-4} alkylene-QR^a, C_{2-6} alkenyleneQR^a; C_{1-4} alkyleneQC₁₋₄alkyleneQR^a,



and a spiro substituent having a structure

- 125 -



;

R^2 is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, C_{2-6} alkenyl, C_{1-3} alkylenearyl, aryl C_{1-3} alkyl, aryl, heteroaryl, $C(=O)R^a$, $C(=O)NR^aR^b$, $C(=O)NR^bR^c$, $C(=S)-NR^aR^b$, $C(=S)NR^bR^c$, OR^a , NR^aR^b , NR^bR^c , SO_2R^a , $SO_2NR^aR^b$, $S(=O)R^a$, $S(=O)NR^aR^b$, $C(=O)NR^aC_{1-4}$ alkylene OR^a , $C(=O)-NR^aC_{1-4}$ alkyleneHet, $C(=O)C_{1-4}$ alkylenearyl, $C(=O)C_{1-4}$ alkyleneheteroaryl, C_{1-4} alkylenearyl, C_{1-4} alkylene-heteroaryl, C_{1-4} alkyleneHet, C_{1-4} alkylene $C(=O)C_{1-4}$ alkylenearyl, C_{1-4} alkylene $C(=O)C_{1-4}$ alkyleneheteroaryl, C_{1-4} alkylene $C(=O)Het$, C_{1-4} alkylene $C(=O)NR^bR^c$, C_{1-4} alkylene OR^a , C_{1-4} alkylene $NR^aC(=O)R^a$, C_{1-4} alkylene OC_{1-4} alkylene OR^a , C_{1-4} alkylene NR^bR^c , C_{1-4} alkylene $C(=O)OR^a$, and C_{1-4} alkylene OC_{1-4} alkylene $C(=O)OR^a$;

R^3 is selected from the group consisting of hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, aryl, heteroaryl, aryl C_{1-3} alkyl, heteroaryl C_{1-3} alkyl, C_{1-3} alkylenearyl, C_{1-3} alkyleneHet, C_{3-8} cycloalkyl, and C_{3-8} heterocycloalkyl;

Y is selected from the group consisting of $C(=O)$, $C(=O)Z$, SO , SO_2 , $C(=S)$, $C(R^a)_2$, and $CR^a=CR^a$;

Z is $(CH_2)_t$ or $C\equiv C$;


A is aryl or heteroaryl and is selected from the group consisting of optionally substituted

- 126 -

5- or 6-membered aromatic rings and optionally substituted fused bicyclic ring systems, either carbocyclic or containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and containing at least one aromatic ring;

R^4 is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, halo, $C(=O)OR^b$, $NHC(=O)C_{1-3}alkyleneN(R^b)_2$, NO_2 , $C(=O)OR^b$, OR^b , CF_3 , OR^a , CN , $OC(=O)R^b$, $arylOR^b$, Het , $NR^aC(=O)C_{1-3}alkyleneC(=O)-OR^a$, $arylOC_{1-3}alkyleneNR^aR^b$, $arylOC(=O)R^a$, $C_{1-4}alkylene-C(=O)OR^b$, $OC_{1-4}alkyleneC(=O)OR^b$, $C_{1-4}alkyleneOC_{1-4}-alkyleneC(=O)OR^b$, $C(=O)NR^bSO_2R^c$, $C_{1-4}alkyleneNR^bR^c$, $C_{2-6}alkenyleneNR^bR^c$, $C(=O)NR^bC_{1-4}alkyleneOR^b$, $C(=O)-NR^bC_{1-4}alkyleneHet$, $OC_{2-4}alkyleneNR^bR^c$, $OC_{1-4}alkylene-CH(OR^b)CH_2NR^bR^c$, $OC_{1-4}alkyleneHet$, $OC_{2-4}alkyleneOR^b$, $OC_{2-4}alkyleneNR^bC(=O)OR^c$, $NR^bC_{1-4}alkyleneNR^bR^c$, $NR^bC(=O)-R^c$, $NR^bC(=O)NR^bR^c$, $N(SO_2C_{1-4}alkyl)_2$, $NR^b(SO_2C_{1-4}alkyl)$, $SO_2NR^bR^c$, OSO_2CF_3 , $C(=O)R^b$, $C_{1-3}alkylenearyl$, $C_{1-4}-alkyleneHet$, $C_{1-6}alkyleneOR^b$, $C_{1-3}alkyleneN(R^b)_2$, NR^bR^c , $C(=O)NR^bR^c$, $NHC(=O)C_{1-3}alkylenearyl$, $NHC(=O)C_{1-3}alkyleneheteroaryl$, $C_{3-8}cycloalkyl$, $C_{3-8}heterocycloalkyl$, $arylOC_{1-3}alkyleneN(R^b)_2$, $arylOC(=O)R^b$, $NHC(=O)C_{1-3}-alkyleneC_{3-8}heterocycloalkyl$, $NHC(=O)C_{1-3}alkyleneHet$, $NHC(=O)haloC_{1-6}alkyl$, and

- 127 -



;

R^5 , independently, is selected from the group consisting of halo, NR^aR^b , NO_2 , $\text{C}_{1-6}\text{alkyl}$, oxo, and OR^a ;

or R^4 and R^5 are taken together to form a 3- or 4-membered alkylene or alkenylene chain component of a 5- or 6-membered ring, optionally containing at least one heteroatom;

R^a is selected from the group consisting of hydrogen, $\text{C}_{1-6}\text{alkyl}$, cyano, aryl, aryl $\text{C}_{1-3}\text{alkyl}$, $\text{C}_{1-3}\text{alkylenearyl}$, heteroaryl, heteroaryl $\text{C}_{1-3}\text{alkyl}$, and $\text{C}_{1-3}\text{alkyleneheteroaryl}$;

R^b is selected from the group consisting of hydrogen, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-8}\text{cycloalkyl}$, $\text{C}_{1-3}\text{alkyleneN}(\text{R}^a)_2$, aryl, aryl $\text{C}_{1-3}\text{alkyl}$, $\text{C}_{1-3}\text{alkylenearyl}$, heteroaryl, heteroaryl $\text{C}_{1-3}\text{alkyl}$, and $\text{C}_{1-3}\text{alkyleneheteroaryl}$;

R^c is selected from the group consisting of hydrogen, $\text{C}_{1-6}\text{alkyl}$, aryl, heteroaryl, aryl $\text{C}_{1-3}\text{alkyl}$, heteroaryl $\text{C}_{1-3}\text{alkyl}$, $\text{C}_{1-3}\text{alkyleneN}(\text{R}^a)_2$, $\text{C}_{1-6}\text{alkylenearyl}$, $\text{C}_{1-6}\text{alkyleneHet}$, halo $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-8}\text{cycloalkyl}$, $\text{C}_{3-8}\text{heterocycloalkyl}$, Het, $\text{C}_{1-3}\text{alkyleneheteroaryl}$, $\text{C}_{1-6}\text{alkyleneC}(=\text{O})\text{OR}^a$, and $\text{C}_{1-3}\text{alkyleneC}_{3-8}\text{heterocycloalkyl}$;

- 128 -

or R^b and R^c are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;

Q is O, S, or NR^d;

C is O, S, or NR^d;

D is O, S, or NR^a;

E is CR^a or N;

F is CR^a, C(R^a)₂, or NR^d;

R^d is null or is selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl, heteroaryl, arylC₁₋₃alkyl, heteroarylC₁₋₃alkyl, C₁₋₃alkylenearyl, and C₁₋₃alkyleneheteroaryl;

Het is a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C₁₋₄alkyl or C(=O)OR^a;

n is 0 or 1;

p is 0, 1, 2, or 3;


q is 0, 1, 2, 3, or 4;

t is 1, 2, 3, or 4;


and pharmaceutically acceptable salts and solvates thereof.

- 129 -

2. The compound of claim 1 represented by the formula



wherein R¹ is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, an optionally substituted bicyclic ring



wherein the fused ring B is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one to three heteroatoms selected from oxygen, sulfur, and nitrogen;


Y null or is selected from the group consisting of C(=O), C(=O)C≡C, C(=O)(CH₂)_t, SO₂, and C(=S);

A is aryl or heteroaryl and is selected from the group consisting of optionally substituted 5- or 6-membered aromatic rings and optionally substituted fused bicyclic ring systems, either carbocyclic or containing at least one heteroatom se-

- 130 -

lected from the group consisting of oxygen, nitrogen, and sulfur, and containing at least one aromatic ring;

R^4 is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, halo, $C(=O)OR^b$, $NHC(=O)C_{1-3}alkyleneN(R^b)_2$, NO_2 , $C(=O)OR^b$, OR^b , CF_3 , OR^a , CN , $OC(=O)R^b$, arylOR^b, Het, $NR^aC(=O)C_{1-3}alkyleneC(=O)-OR^a$, $arylOC_{1-3}alkyleneNR^aR^b$, $arylOC(=O)R^a$, $C_{1-4}alkyleneC(=O)OR^b$, $OC_{1-4}alkyleneC(=O)OR^b$, $C(=O)NR^bSO_2R^c$, $C_{1-4}alkyleneNR^bR^c$, $C_{2-6}alkenyleneNR^bR^c$, $C(=O)NR^bC_{1-4}alkyleneOR^b$, $NR^bC_{1-4}alkyleneNR^bR^c$, $NR^bC(=O)R^c$, $NR^bC(=O)NR^bR^c$, OSO_2CF_3 , $C(=O)R^b$, $C_{1-3}alkylenearyl$, $C_{1-4}alkyleneHet$, $C_{1-6}alkyleneOR^b$, $C_{1-3}alkyleneN(R^b)_2$, NR^bR^c , $C(=O)NR^bR^c$, $NHC(=O)C_{1-3}alkylenearyl$, $NHC(=O)C_{1-3}alkyleneheteroaryl$, $NHC(=O)C_{1-3}alkyleneHet$, $NHC(=O)haloC_{1-6}alkyl$, and



R^5 , independently, is selected from the group consisting of halo, NR^aR^b , NO_2 , C_{1-6} alkyl, oxo, and OR^a ;

R^a and R^b , independently, are selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, $arylC_{1-3}alkyl$, $C_{1-3}alkylenearyl$, heteroaryl, heteroaryl $C_{1-3}alkyl$, and $C_{1-3}alkyleneheteroaryl$;

- 131 -

R^c is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, aryl C_{1-3} alkyl, heteroaryl C_{1-3} alkyl, C_{1-3} alkyleneN(R^a)₂, C_{1-6} alkylene-aryl, C_{1-6} alkyleneHet, halo C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, Het, C_{1-3} alkyleneheteroaryl, C_{1-6} alkyleneC(=O)OR^a, and C_{1-3} alkylene C_{3-8} heterocycloalkyl;

or R^b and R^c are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;

Het is a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C_{1-4} alkyl or C(=O)OR^a;


p is 0, 1, 2, or 3;

t is 1, 2, 3, or 4;

and pharmaceutically acceptable salts and solvates thereof.

- 132 -

3. The compound of claim 1 represented by the formula






and pharmaceutically acceptable salts and hydrates thereof.

4. The compound of claim 1 wherein q is 0.


5. The compound of claim 1 wherein R⁰ is selected from the group consisting of C₁₋₆alkyl, aryl, heteroaryl, C₃₋₈heterocycloalkyl, OR^a, C(=O)OR^a, C₁₋₄alkyleneNR^aR^b, OC(=O)R^a, C(=O)R^a, NR^bR^c, C₃₋₈cycloalkyl, C₃₋₈cycloalkylQ, C(=O)NR^aR^b, and C(=O)NR^bR^c.

- 133 -

6. The compound of claim 1 wherein R¹ is selected from the group consisting of C₁₋₄alkyleneQR^a, C₁₋₄alkyleneQC₁₋₄alkyleneQR^a, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, C₁₋₆alkyl,




, and




- 134 -

7. The compound of claim 1 wherein R¹ is the optionally substituted bicyclic ring






8. The compound of claim 7 wherein R¹ is








and wherein m is an integer 1 or 2, and G, independently, are C(R^a)₂, O, S, or NR^a.

- 135 -





9. The compound of claim 1 wherein R¹ is selected from the group consisting of






- 136 -





- 137 -



- 138 -



-CH₂OR^a, -CH₂OCH₂OR^a,




- 139 -

10. The compound of claim 1 wherein the R² group is selected from the group consisting of hydrogen, aryl, heteroaryl, OR^a, NR^aR^b, NR^bR^c, C₁₋₄-alkyleneHet, C₁₋₄alkyleneheteroaryl, C₁₋₄alkylenearyl, C₁₋₄alkyleneC(=O)C₁₋₄alkylenearyl, C₁₋₄alkyleneC(=O)OR^a, C₁₋₄alkyleneC(=O)NR^bR^c, C₁₋₄alkyleneC(=O)Het, C₁₋₄alkyleneNR^bR^c, C₁₋₄alkyleneNR^aC(=O)R^a, and C₁₋₄alkyleneOC₁₋₄-alkyleneOR^a.

11. The compound of claim 1 wherein A is selected from the group consisting of phenyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3,4-oxatriazolyl, 1,2,3,5-oxatriazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, indolizinyl, indolyl, isoindolyl, benzo[b]-furanyl, benzo[b]thienyl, 1H-indazolyl, benzimidazolyl, benzthiazoyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, indenyl, and naphthyl.

- 140 -




12. The compound of claim 1 wherein R^4 is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, halo, $C(=O)OR^b$, $NHC(=O)-C_{1-3}$ alkylene $N(R^b)_2$, NO_2 , $C(=O)OR^b$, OR^b , CF_3 , OR^a , CN , $OC(=O)R^b$, aryl OR^b , Het, $NR^aC(=O)C_{1-3}$ alkylene $C(=O)OR^a$, aryl OC_{1-3} alkylene NR^aR^b , aryl $OC(=O)R^a$, C_{1-4} alkylene $C(=O)-OR^b$, OC_{1-4} alkylene $C(=O)OR^b$, $C(=O)NR^bSO_2R^c$, C_{1-4} alkylene- NR^bR^c , C_{2-6} alkenylene NR^bR^c , $C(=O)NR^bC_{1-4}$ alkylene OR^b , NR^bC_{1-4} alkylene NR^bR^c , $NR^bC(=O)R^c$, $NR^bC(=O)NR^bR^c$, OSO_2CF_3 , $C(=O)R^b$, C_{1-3} alkylenearyl, C_{1-4} alkyleneHet, C_{1-6} alkylene OR^b , C_{1-3} alkylene $N(R^b)_2$, NR^bR^c , $C(=O)NR^bR^c$, $NHC(=O)C_1-C_3$ alkylenearyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, $NHC(=O)C_{1-3}$ alkyleneHet, $NHC(=O)haloC_{1-6}$ alkyl, and








13. The compound of claim 1 wherein R^3 is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, and heteroaryl.

- 141 -


14. The compound of claim 1 wherein q is 0 or R⁰ is selected from the group consisting of halo, methyl, trifluoromethyl, and trifluoromethoxy; R¹ is selected from the group consisting of




- 142 -



- 143 -





, and









;


R^2 is selected from the group consisting of hydrogen, C_{1-6} alkyl, $C(=O)NR^bR^c$, and C_{1-4} alkyleneHet; R^3 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, aryl, and heteroaryl; Y is null, or Y is selected from the group consisting of $C(=O)$, $C(=O)C\equiv C$, $C(=O)CH_2$, $C(=O)CH_2CH_2$, and SO_2 ; A is




- 144 -





- 145 -








, or









R^4 is selected from the group consisting of H, $NHC(=O)CH_3$, $N(CH_3)_2$, $C(=O)NH_2$, $NHCH_3$, NO_2 , NH_2 , Br, $C(=O)CH_3$, OCH_3 , CH_2OCH_3 , $NHC(=O)CH_2N(CH_3)_2$, $CH_2N(CH_3)_2$, CH_3 , Cl, $NHC(=O)CH_2CO_2H$,









- 146 -







- 147 -



- 148 -




- 149 -



, and

- 150 -



; and

p is 0 or R^5 groups, independently, are selected from the group consisting of CH_3 , Cl, oxo, and OCH_3 .

15. The compound of claim 14 wherein R^2 is hydrogen and R^3 is hydrogen.

- 151 -

16. A compound selected from the group consisting of

1-(2H-benzo[d]1,3-dioxolan-5-yl)(1,2,3,4-tetrahydro- β -carbolin-2-yl)-2-naphthyl ketone;
1-(2H-benzo[d]1,3-dioxolan-5-yl)(1R)(1,2,3,4-tetrahydro- β -carbolin-2-yl)2-naphthyl ketone;
1-(1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)-1-phenylmethanone;
N-{4[1-(1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carboline-2-yl)-methanoyl]phenyl}acetamide;
1-(1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)-1-(4-methylaminophenyl)methanone;
1-(1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)-1-(4-dimethylaminophenyl)methanone;
4-[1-(1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)methanoyl]benzamide;
1-(1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)-3-phenylpropynone;
3-(2-aminophenyl)-1-(1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)propan-1-one;
N-{4-[1-(1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)methanoyl]phenyl}-2-phenylacetamide;
1-(1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)-3-phenylpropan-1-one;
1-(1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)-1-(3H-benzoimidazol-5-yl)methanone;
2-benzo[b]thiophen-3-yl-1-(1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)ethanone;
2-[(1-(2H-benzo[d]1,3-dioxolan-5-yl)-(1R)-(1,2,3,4-tetrahydro- β -carbolin-2-yl)sulfonyl]-5-chloro-3-methylbenzo[b]thiophene;
2-(1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro- β -carbolin-2-yl)-6,7-dimethoxy-3H-quinazolin-4-one;

- 152 -

1-benzo[1,3]dioxol-5-yl-2-(4-chloro-6,7-dimethoxy-quinazolin-2-yl)-2,3,4,9-tetrahydro-1H-β-carboline;
1-benzo[1,3]dioxol-5-yl-2-(6,7-dimethoxyquinazolin-2-yl)-2,3,4,9-tetrahydro-1H-β-carboline;

and a pharmaceutically acceptable salt or solvate thereof.

17. A compound selected from the group consisting of Examples 13a, 13b, 14-22, 24-44, and 48-87 as disclosed herein,

and a pharmaceutically acceptable salt or solvate thereof.

18. A pharmaceutical composition comprising a compound of claim 1, together with a pharmaceutically acceptable diluent or carrier.

19. A method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition comprising a compound of claim 1, together with a pharmaceutically acceptable diluent or carrier.

20. The method of claim 19 wherein the condition is male erectile dysfunction.

21. The method of claim 20 wherein the treatment is an oral treatment.

22. The method of claim 19 wherein the condition is female arousal disorder.

- 153 -

23. The method of claim 22 wherein the treatment is an oral treatment.

24. The method of claim 19 wherein the condition is selected from the group consisting of stable angina, unstable angina, variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, malignant hypertension, pheochromocytoma, acute respiratory distress syndrome, congestive heart failure, acute renal failure, chronic renal failure, atherosclerosis, a condition of reduced blood vessel patency, a peripheral vascular disease, a vascular disorder, thrombocytopenia, an inflammatory disease, myocardial infarction, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, peptic ulcer, a gut motility disorder, postpercutaneous transluminal coronary angioplasty, carotid angioplasty, postbypass surgery graft stenosis, osteoporosis, preterm labor, benign prostatic hypertrophy, and irritable bowel syndrome.

25. A method of treating a condition where inhibition of a cGMP-specific PDE is of therapeutic benefit, in a human or a nonhuman animal body, comprising administering to said body a therapeutically effective amount of a compound of claim 1.

- 154 -

26. A method for the curative or prophylactic treatment of male erectile dysfunction or female arousal disorder, comprising administration of an effective dose of a compound of claim 1, and pharmaceutically acceptable salts and solvates thereof, to an animal.

27. Use of a compound of claim 1 for the manufacture of a medicament for the curative or prophylactic treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number
WO 02/064590 A3(51) International Patent Classification⁷: C07D 471/04,
519/00, A61K 31/437, A61P 9/00, 15/10 // (C07D 471/04,
221/00, 209/00) (C07D 519/00, 471/00, 471/00)avenue de Quebec, F-91940 Les Ulis (FR). **GOSMINI,**
Roamin, Luc, Marie [FR/FR]; Centre de Recherche
Glaxo Smith Kline Courtaboeuf, ZA de Courtaboeuf, 25,
avenue de Quebec, F-91940 Les Ulis (FR).

(21) International Application Number: PCT/US01/49393

(74) Agent: **NAPOLI, James, J.**; Marshall, Gerstein & Borun,
6300 Sears Tower, 233 South Wacker Drive, Chicago, IL
60606 (US).(22) International Filing Date:
18 December 2001 (18.12.2001)(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/268,158 12 February 2001 (12.02.2001) US(71) Applicant (for all designated States except US): **LILLY**
ICOS LLC [US/US]; 1209 Orange Street, Wilmington, DE
19801 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SAWYER, Jason,**
Scott [US/US]; 5718 North Winthrop Avenue, Indianapolis,
IN 46220 (US). **ORME, Mark, W.** [US/US]; 4235
Francis Avenue #203, Seattle, WA 98103 (US). **BOM-**
BRUN, Agnes [FR/FR]; Maison Caloni, 1153 Route du
Saleve, F-74560 Monnetier Mornex (FR). **BOUILLOT,**
Anne [FR/FR]; Centre de Recherche Glaxo Smith Kline
Courtaboeuf, ZA de Courtaboeuf, 25, avenue de Quebec,
F-91940 Les Ulis (FR). **DODIC, Nerina** [FR/FR]; Centre
de Recherche Glaxo Smith Kline Courtaboeuf, ZA de
Courtaboeuf, 25, avenue de Quebec, F-91940 Les Ulis
(FR). **SIERRA, Michael** [FR/FR]; Centre de Recherche
Glaxo Smith Kline Courtaboeuf, ZA de Courtaboeuf, 25,(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).


(73) Designated States:

— with international search report

(88) Date of publication of the international search report:
27 February 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CARBOLINE DERIVATIVES



(57) Abstract: Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents. In particular, the invention relates to compounds that are potent and selective inhibitors of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase (cGMP-specific PDE), in particular PDE5, and have utility in a variety of therapeutic areas wherein such inhibition is considered beneficial, including the treatment of cardiovascular disorders and erectile dysfunction.

INTERNATIONAL SEARCH REPORT

International	cation No
PCT/US 01/49393	

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D471/04 C07D519/00 A61K31/437 A61P9/00 A61P15/10 //((C07D471/04, 221:00, 209:00), (C07D519/00, 471:00, 471:00))										
According to International Patent Classification (IPC) or to both national classification and IPC										
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D A61K A61P										
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched										
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, CHEM ABS Data										
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%;">Category</th> <th style="width: 80%;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="width: 10%;">Relevant to claim No.</th> </tr> <tr> <td style="text-align: center;">A</td> <td>WO 97 43287 A (ICOS) 20 November 1997 (1997-11-20) page 17, lines 8-11 and line 33 to page 18, line 5 claim 1 -----</td> <td style="text-align: center;">1,18,19, 25</td> </tr> <tr> <td style="text-align: center;">X</td> <td>GREMMEN, CHRISTIAAN ET AL: "Enantiopure Tetrahydro-.beta.-carbolines via Pictet-Spengler Reactions with N-Sulfinyl Tryptamines" ORGANIC LETTERS (2000), 2(13), 1955-1958 , XP002214245 table 1, compound 11 ----- -/-</td> <td style="text-align: center;">1</td> </tr> </table>		Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	A	WO 97 43287 A (ICOS) 20 November 1997 (1997-11-20) page 17, lines 8-11 and line 33 to page 18, line 5 claim 1 -----	1,18,19, 25	X	GREMMEN, CHRISTIAAN ET AL: "Enantiopure Tetrahydro-.beta.-carbolines via Pictet-Spengler Reactions with N-Sulfinyl Tryptamines" ORGANIC LETTERS (2000), 2(13), 1955-1958 , XP002214245 table 1, compound 11 ----- -/-	1
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.								
A	WO 97 43287 A (ICOS) 20 November 1997 (1997-11-20) page 17, lines 8-11 and line 33 to page 18, line 5 claim 1 -----	1,18,19, 25								
X	GREMMEN, CHRISTIAAN ET AL: "Enantiopure Tetrahydro-.beta.-carbolines via Pictet-Spengler Reactions with N-Sulfinyl Tryptamines" ORGANIC LETTERS (2000), 2(13), 1955-1958 , XP002214245 table 1, compound 11 ----- -/-	1								
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.										
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed										
T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family										
Date of the actual completion of the international search 20 September 2002										
Date of mailing of the international search report 09/10/2002										
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016										
Authorized officer Alfaro Faus, I										

INTERNATIONAL SEARCH REPORT

International
cation No
PCT/US 01/49393

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YOU, YE-CHENG ET AL: "Application of DDQ in the synthesis of beta.-carboline alkaloid" retrieved from STN Database accession no. 133:105190 XP002214253 RN = 284037-14-5 & HECHENG HUAXUE (2000), 8(1), 83-86 , ---	1
X	KAWATE, TOMOHIKO ET AL: "Chiral auxiliary approach to the asymmetric Pictet-Spengler reaction of tryptamines" HETEROCYCLES (1999), 50(2), 1033-1039 , XP002214246 table, compounds 4+5 a-c ---	1
X	CARNIAUX, JEAN-FRANCOIS ET AL: "Synthesis of a novel fused tricyclic quinolone system via oxidation of 1,2,3,4-tetrahydro-.beta.-carbolines" TETRAHEDRON LETTERS (1997), 38(17), 2997-3000 , XP004059081 compound 4d ---	1
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LEGSEIR, B. ET AL: "Synthesis of optically active tetrahydro-.beta.-carbolines by the Pictet-Spengler reaction" retrieved from STN Database accession no. 125:222235 XP002214254 RNs = 181492-02-4; 181492-00-2 & JOURNAL DE LA SOCIETE ALGERIENNE DE CHIMIE (1996), 6(1), 17-27 , ---	1
X	SOE, THAN ET AL: "Asymmetric Pictet-Spengler reaction with chiral N-(.beta.-3- indolyl)ethyl-1-methylbenzylamine" TETRAHEDRON LETTERS (1995), 36(11), 1857-60 , XP004028505 table 3 --- -/-	1

INTERNATIONAL SEARCH REPORT

Internation
ation No
PCT/US 01/49393

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PARSONS, RODNEY L. ET AL: "Total synthesis of strychnan- and aspidospermatan-type alkaloids. 2. Generation of 15-(3-furanyl) ABCE tetracyclic intermediates" JOURNAL OF ORGANIC CHEMISTRY (1993), 58(26), 7482-9 , XP002214249 page 7487, column 1, paragraph 2 ---	1
X	SOERENS, D. ET AL: "Study of the Pictet-Spengler reaction in aprotic media: synthesis of the beta.-galactosidase inhibitor, pyridindolol" J. ORG. CHEM. (1979), 44(4), 535-45 , XP002214250 table III, compound 7d ---	1
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HAYASHI, MASATOSHI ET AL: "Preparation of tetrahydro-.beta.-carboline derivatives as lipid peroxidation inhibitors and antiulcer agents" retrieved from STN Database accession no. 116:235613 XP002214255 RNs 141218-51-1; 141218-52-2; 141218-84-0; 141218-86-2; 141230-36-6 & JP 03 287586 A (TAISHO PHARMACEUTICAL CO., LTD., JAPAN) 18 December 1991 (1991-12-18) ---	1,18
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YANG, TSANG HSIUNG ET AL: "Synthesis of some annomontine analogs" retrieved from STN Database accession no. 112:119208 XP002214256 RNs 125707-22-4; 125707-23-5; 125707-20-2 & CHUNG-HUA YAO HSUEH TSA CHIH (1989), 41(3), 239-46 , --- -/-	1

INTERNATIONAL SEARCH REPORT

International	Application No
PCT/US 01/49393	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MISZTAL, STANISLAW: "Synthesis of 6-substituted perhydropyrido(1,2-c:2',1'-e)imidazo(3,4- c)indole" retrieved from STN Database accession no. 76:72451 XP002214257 RN = 35258-05-0 & DISS. PHARM. PHARMACOL. (1971), 23(4), 409-17 ,</p> <p>---</p> <p>JACKSON, ANTHONY HUGH ET AL: "Electrophilic substitution in indoles. II. Formation of 3,3-spirocyclic indole derivatives from tryptamines and their rearrangement to beta.-carbolines" TETRAHEDRON (1968), 24(1), 403-13 , XP002214251 page 410, lines 48-53</p> <p>---</p> <p>WO 01 87038 A (ORTHO MCNEIL PHARM INC) 22 November 2001 (2001-11-22) examples claims 1,10-14</p> <p>---</p> <p>SEEFELD, M. A. ET AL: "Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido'3,4-b!indoles as potential antibacterial agents" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001), 11(17), 2241-2244 , XP002214252 compound 17</p> <p>---</p> <p>WO 01 87882 A (ORTHO MCNEIL PHARM INC) 22 November 2001 (2001-11-22) examples 1,1A,2,2A,12-18,46,49,52,55,65,66,83-86</p> <p>---</p> <p>-/-</p>	1
X		1
P, X		1,18-20, 22,24
P, X		1,18
P, X		1

INTERNATIONAL SEARCH REPORT

Internation: PCT/US 01/49393

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHERNOV, S. V. ET AL: "Synthesis of diterpene.beta.-carbolines" retrieved from STN Database accession no. 136:401892 XP002214258 RNs = 429679-72-1; 429679-76-5; 429679-77-6 429679-71-0 & DOKLADY AKADEMII NAUK (2001), 381(5), 643-646 ,</p>	1
E	<p>WO 02 062339 A (SMITHKLINE BEECHAM) 15 August 2002 (2002-08-15) claims 1,6</p>	1,18

INTERNATIONAL SEARCH REPORTInternal application No.
PCT/US 01/49393**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 19 – 26 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International	Classification No
PCT/US	01/49393

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9743287	A 20-11-1997	AT 215950	T	15-04-2002
		AU 711885	B2	21-10-1999
		AU 2891097	A	05-12-1997
		BG 102879	A	30-09-1999
		BR 9709230	A	10-08-1999
		CN 1218471	A , B	02-06-1999
		CZ 9803585	A3	17-03-1999
		DE 69711882	D1	16-05-2002
		EE 9800390	A	15-06-1999
		WO 9743287	A1	20-11-1997
		EP 0912567	A1	06-05-1999
		HU 9901478	A2	30-08-1999
		JP 2000513717	T	17-10-2000
		KR 2000010918	A	25-02-2000
		MD 980248	A	31-10-2000
		NO 985222	A	11-01-1999
		PL 329875	A1	12-04-1999
		SK 154498	A3	18-01-2000
		TR 9802282	T2	22-03-1999
		US 6117881	A	12-09-2000
		US 6306870	B1	23-10-2001
JP 3287586	A 18-12-1991	NONE		
WO 0187038	A 22-11-2001	AU 6116701	A	26-11-2001
		WO 0187038	A2	22-11-2001
		US 2002010189	A1	24-01-2002
WO 0187882	A 22-11-2001	AU 6117801	A	26-11-2001
		WO 0187882	A2	22-11-2001
		US 2002010183	A1	24-01-2002
WO 02062339	A 15-08-2002	WO 02062339	A1	15-08-2002